CURRICULUM VITAE

December, 2011

Name: **J. Silvio Gutkind**

Work Address: Oral and Pharyngeal Cancer Branch
National Institute of Dental and Craniofacial Research
National Institutes of Health
30 Convent Drive
Building 30, Room 211
Bethesda, Maryland 20892-4340
Tel: (301) 496-6259
Fax: (301) 402-0823
E-mail: sg39v@nih.gov
Web Page:
http://www.nidcr.nih.gov/Research/NIDCRLaboratories/OralPharyngeal/SilvioGutkind.htm

Education:

1976-1980	Pharmacy Degree (M.Sc.), University of Buenos Aires, Argentina
1976-1983	Biochemistry Degree (M.Sc.), University of Buenos Aires, Argentina.
1985	Ph.D. in Pharmacy and Biochemistry, University of Buenos Aires, Argentina

Employment History:

1998-present	Chief, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, USA
1997-present	Chief, Cell Growth Regulation Section and Molecular Carcinogenesis Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, NIH, Bethesda, USA
1996-1997	Acting Chief, Oral and Pharyngeal Cancer Branch, National Institute of Dental Research, NIH, Bethesda, USA
1993-1997	Chief, Molecular Signaling Unit, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA.
1992-1993	Head, Molecular Signaling Group, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA.
1989-1992	Visiting Associate, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA.
1988-1989	Fogarty Visiting Fellow, Laboratory of Cellular Development and Oncology, National Institute of Dental Research, NIH, Bethesda, USA.
1987-1988	Fogarty Visiting Fellow, NIDR, Guest Researcher at the Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH, Bethesda, USA.

1986-1987	International Fogarty Fellow, Laboratory of Clinical Science, National Institute of Mental Health, NIH, Bethesda, USA.
1983-1986	Research Assistant, Department of Pharmacology, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina.
1981-1983	Part-time Instructor, Department of Pharmacology, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina.
1979-1980	Part-time Instructor, Department of Organic Chemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina.

Honors and Awards:

2011	Raices Award, Ministry of Science, Presidency of Argentina, for scientific contributions and efforts in enhancing research training and technology development, Argentina.
	Keynote Speaker, MinnCResT Symposium: Head & Neck Cancer, University of Minnesota, Minneapolis, MN
	Keynote Speaker, (IADR, Chile) Asociación Internacional de Investigación Dental – División Chile, Chile
	Keynote Speaker, NCI Frederick Spring Research Festival, Frederick, MD
	Visiting Professor, Georgetown University, Washington DC
2010	Visiting Professor and Clinical Ground Round Speaker, Memorial Sloan Kettering Cancer Center, New York, NY
	Keynote Speaker, 6th Annual International Head and Neck Symposium, Los Angeles, CA, July 2010
	Honorary Professor, University of Buenos Aires, Argentina
	Keynote Speaker, The First South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2010, Cordoba, Argentina
2009	Keynote Lecture, Symposium on Molecular Medicine, Virginia Commonwealth University, Richmond, VA
	Keynote Speaker, School of Dentistry University of Michigan Research Day, Ann Arbor, MI
	Keynote speaker at the Annual Meeting of the Chilean Society of Biochemistry and Molecular Biology, Concepcion, Chile
	Keynote Inaugural Lecture, Annual meeting of the Argentine Society of Research in Biochemistry and Molecular Biology, Tucuman, Argentina
2008	Hyman Niznik Memorial Keynote Lectureship, Annual Joint Meeting of the Great Lakes: G Protein-Coupled Receptor Retreat, Bromont, Canada
	Merk Frosst Lecture, Institut de Recherches Cliniques de Montreal (IRCM), Montreal, Canada
	R.M. Tiwari Oration, National Conference, Foundation for Head and Neck Oncology, Bhubaneswar, India
2007	Frank Brook Memorial Lecture, American Pancreatic Association, Chicago, IL
2006	Elected, Co-chair, Gordon Research Conference, “Phosphorylation & G-Protein Mediated Signaling Networks”, 2008
2006	Miguel Aleman Lecture, Miguel Aleman Foundation, Mexico DF, Mexico
2005	NIH Director's Award

2005	Elliot Osserman Award, Israel Cancer Research Foundation
2004	International Association of Dental Research (IADR) Distinguished Scientist Award, Oral Medicine and Pathology
2003	NIH Hispanic Heritage Month Celebration: Hispanic Contributions to Research in the United States, Lecture
2000	NIDCR Director's Exemplary Service Award
1999	EEO Special Achievement Award, NIDCR, NIH
1998	Appointment as member of the Senior Biomedical Research Services (SBRS)
1997	NIDR Director's Exemplary Service Award
1996	NIH Merit Award
1989	Funds for Young Scientists, Travel Award, Organizing Committee of the 7th International Conference on Protein Phosphorylation, Kobe, Japan
1986	International Fogarty Fellowship, National Institutes of Health, USA
1983	Gold Medal Award and Diploma of Honor, first rank student of the School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina.

Editorial Responsibilities:

1998-2003	Member, Editorial Board, Journal of Biological Chemistry
1998-2000	Editor, Book on Signaling Networks and Cell Cycle Control, Humana Press
2000-2003	Co-Editor, Book on Head and Neck Cancer, Emerging Perspectives, Wiley & Co
2000-present	Member, Editorial Board, Oral Oncology
2001-present	Member, Editorial Board, Biochemistry
2001-2006	Member, Editorial Board, Revista de Oncologia, Mexico-Spain
2002-2003	Co-Editor, Book on Signal Transduction and Human Disease, Wiley & Co
2002-present	Member, Faculty 1000, Reviewing Editor
2003-2005	Member, Editorial Board, Drug Discovery Today: Disease Mechanisms
2005-present	Member, Editorial Board, Molecular Biology of the Cell
2006-present	Member, Editorial Board, Current BioData Lipid Signalling
2008-present	Member, Editorial Board, Cancer Prevention Research
2009-present	Member, Editorial Board, Molecular and Cellular Biology
2009-present	Member, Editorial Board, Genes & Cancer
2010-present	Member, Editorial Board, Journal of Biological Chemistry

Ad-hoc Reviewer:

Biochemical and Biophysical Acta; Blood; British Journal of Cancer; Cancer Cell; Cancer Research; Clinical Cancer Research; Cell; Cell Stem Cell; Cell Growth and Differentiation; Clinical Cancer Research; Current Biology; Developmental Cell; EMBO Journal; FEBS letters; Journal of Biological Chemistry; Journal of Cell Biology; Journal of Cell Physiology; Journal of Clinical Investigation; Journal of Immunology; Journal of Neurochemistry; Molecular and Cellular Biology; Molecular and Cellular Neurobiology; Molecular Cell; Molecular Pharmacology, Nature; Nature Cell Biology; Nature Genetics; Nature Medicine; Oncogene; Oral Oncology; Trends in Biological Science; Proceedings of the National Academy of Science, USA; Science

Membership and Activity in Professional Societies:

American Association for the Advancement of Science (AAAS)
American Society of Microbiology (ASM)
American Society of Molecular Biology (ASMB)
International Association for Dental Research (IADR)
American Association for Dental Research (AADR)
Founding Member, International Academy of Oral Oncology (IAOO)

Extramural Activities:

NIH Extramural

1997	Ad-hoc member, Program Project Review Panel, DER, NCI
1999-2000	Member, Grant Review Panel, Division of Basic Science, NCI
2002	Ad-hoc Member, NIH Study Section, CDF-4
2002	Co-chair, FY2004 NIDCR Initiatives, Head and Neck Cancer, Molecular Anatomy of Head and Neck Cancer: A Genomic/Proteomic Approach
2003-2004	Member AIDS Malignancies Consortium, NIH
2003	Member, Biological Pathways and Networks Group, NIH Road Map Initiative
2004-2007	Member, NIH extramural Study Section, NDT
2005	Member, NIGMS, Special Emphasis Review Panel
2005	Member, Review Panel NRSA-NIH, Fellowships: Molecular and Cellular Mechanisms
2007	Ad-hoc Member, NIH extramural Study Section, Intercellular Interactions (ICI)
2008	Ad-hoc Member, NIH extramural Study Section, Tumor Microenvironment (TME)
	Ad-hoc Member, NIH extramural Study Section, Molecular and Integrative Signal Transduction (MIST)
2008-present	Member, NIH extramural Study Section, Tumor Microenvironment (TME)
2009	Member, NIH extramural Study Section, NIH Challenge Grants in Health and Science Research, American Recovery and Reinvestment Act of 2009
2010	Site Visit Review Panel, Laboratory of Biochemistry, Office of Biotechnology Products, Center for Biologics Evaluation and Research, FDA

Extramural

1995-2004	Reviewer, Welcome Trust Foundation
1997-2006	Reviewer, National Science Foundation
1998-2001	Member, Cancer Genome Anatomy Program
1999-2002	Advisor, Howard Hughes Research Scholar Program
2002-2004	Member, External Advisory Board, The Johns Hopkins University, School of Medicine, Spore in Head and Neck Cancer

2002-present	Member, External Advisory Panel, South Carolina COBRE for Oral Health in Vulnerable Populations, South Carolina
2002-2003	Member, Reviewing Panel, FAMRI. Flight Attendants Medical Research Institute, Young Clinical Scientist Awards Program
2003	Reviewer, Phillip Morris Research Grants
2005-present	Adjunct Professor, University of Maryland, Dental School
2007	Reviewer, Phillip Morris Research Grants

International

1995-2004	Reviewer, Welcome Trust Foundation
1996-present	Reviewer, The Israel Science Foundation
1997-present	Reviewer, Italian Association for Scientific Research
1997-2002	Reviewer, German-Israeli Foundation for Scientific Research & Development
1997-2006	Reviewer, National Science Foundation
1998-2001	Member, Cancer Genome Anatomy Program
1998-2004	Member, Reviewing Council, FONCYT, Argentina
2003-2005	Member Reviewing Panel, The Israel Cancer Research Foundation
2008-present	Member Scientific Advisory Board, Max Planck Institute for Heart and Lung Research, Munich, Germany
2009	Review Panel, Regional Collaborative Program SFB/TR23, Vascular Differentiation, and Remodeling, Manheim, Germany
2010-present	Comité Científico Asesor Externo de la Red Temática de Investigación Cooperativa en Cáncer (RTICC), Spain
2010-present	Member Reviewing Panel, The Israel Cancer Research Foundation

Invited Presentations (since 2005)

2011-	IMCB Institute of Molecular and Cellular Biology, Singapore Institute for Cancer Research and Treatment, University of Torino, Torino, Italy University of Illinois College of Medicine, Chicago, IL AACR 102 Annual Meeting, Orlando, FL Keynote Speaker, MinnCResT Symposium: Head & Neck Cancer, University of Minnesota, Minneapolis, MN Third Meeting, International Association of Oral Oncology (IAOO), Singapore IADR Annual Meeting, Stem Cells, Reprogramming, Immunomodulation and Cancer session, San Diego, March 2011 IADR Annual Meeting, Stem Cells, New Targets for the Prevention and Treatment of Oral and Head and Neck Cancer session, San Diego, March 2011 Keynote Speaker, (IADR, Chile) Asociación Internacional de Investigación Dental – División Chile, Chile Keynote Speaker, NCI Frederick Spring Research Festival, Frederick, MD Visiting Professor, Georgetown University, Washington DC
2010-	Moores UCSD Cancer Center, Director's Seminar Series, UCSD, CA University of Buenos Aires, Buenos Aires, Argentina

Keynote Speaker, The First South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2010, Cordoba, Argentina
IBYME, Buenos Aires, Argentina
Basic Science Speaker, 92nd Annual Meeting, American Association of Oral and Maxillofacial Surgeons (AAOMS), Chicago, IL
Visiting Professor and Clinical Ground Round Speaker, Memorial Sloan Kettering Cancer Center, New York, NY
University of Cincinnati, Cincinnati, OH
AACR 101st Annual Meeting, Washington, DC
Fudan University, Shanghai, China

2009- Keynote Speaker, U. Michigan School of Dentistry Research Day, Ann Arbor, MI
Symposium on "The Origin of Cancer", Van Andel Institute, Grand Rapids, MI
Keynote Lecture, Symposium on Molecular Medicine, Virginia Commonwealth University, Richmond, VA
Keynote Speaker, Annual Meeting of the Argentinean Society for Biochemistry, n Tucuman, Argentina
Keystone Symposia: Angiogenesis and Lymphangiogenesis in Cancer, Big Sky, MT
FASEB Symposium on Lipid Signaling, Session Chair and Lecture, Carefree, AZ
Van Andel Institute, Origins of Cancer Symposium, Grand Rapids, MI
University of Maryland, Baltimore, MD
University of North Carolina, Chapel Hill, NC
University of Pittsburgh, Pittsburgh, PA
University of Chicago Cancer Research Center, Chicago, IL
Louisiana State University, Head and Neck Surgical Oncology Feist-Weiller Cancer Center, Shreveport, LA
ASPET's Experimental Biology 2009 Symposia on Virally-encoded G-Protein Coupled Receptors as New Drug Targets, New Orleans, LA
Gordon Research Conference, "Molecular Pharmacology", Il Ciocco, Italy
Unidad de Biologia Celular Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, Spain
Centro de Investigacion del Cancer IBMSS, Salamanca, Spain

2008- Clinical Ground Round, MD Anderson, Houston, TX
New York Academy of Science, New York, NY
North America Vascular Biology Organization (NAVBO), Biology of Signaling in the Cardiovascular System Workshop, Hyannis, MA
Vascular Differentiation and Remodeling, Frankfurt, Germany
International Conference on Frontiers of Dental and Craniofacial Research, Beijing, China.
Hyman Niznik Memorial Lectureship, 9th Annual Joint Meeting of the Great Lakes: G Protein-Coupled Receptor Retreat, Bromont, Canada
Merk Frosst Lecture, Institut de Recherches Cliniques de Montreal (IRCM), Montreal, Canada

2007- Frank Brook Memorial Lecture, American Pancreatic Association, Chicago, IL
First Meeting, "The Tumor Angiogenesis Interface", Kloster Seeon, Germany
Second Meeting "Signaling Complexes", Jena, Germany

NIH Research Festival, Angiogenesis Section, Bethesda, MD
Medical College of Georgia, Augusta, GA
Keynote Speaker, "Signal Transduction Meeting", Mexican Biochemical Society, Veracruz, Mexico
International Symposium on "G-protein Signaling", Tokyo, Japan
University of Kyoto, Japan
Cardiovascular Institute, Osaka, Japan
Center for Structural Molecular Biology, Brazilian Synchrotron Light Laboratory, Campinas, SP, Brazil
20th Chicago Signal Transduction Symposium, Chicago Illinois
Gordon Research Conference on "Phosphorylation & G-Protein Mediated Signaling Networks", Biddeford, Maine
Medical University of South Carolina and Hollings Cancer Center, Charleston, SC
Gordon Research Conference, "Molecular Pharmacology", Ventura, CA

2006- National Cancer Institute, Clinical Ground Rounds, NIH, Bethesda, MD
Miguel Aleman Award Lecture, Miguel Aleman Foundation, Mexico DF, Mexico
Center for Research and Advanced Studies (CINVESTA), Mexico DF, Mexico
National Autonomous University of Mexico, Mexico DF, Mexico
NEIHS, Durham, NC
Carnegie Institute, Baltimore, MD
IADR, Brisbane, Australia
University of Sydney, Australia
Centro de Biologia Molecular Severo Ochoa, Madrid, Spain
Annual symposium of the Membrane, Montreal Canada
Gordon Research Conference, "Phosphorylation & G-Protein Mediated Signaling Networks", Biddeford, ME
Thammasat University, Bangkok, Thailand
Naresuan University, Phitsanulok, Thailand
University of North Carolina-Chapel Hill, NC

2005- University of Buenos Aires, School of Exact Sciences, Buenos Aires, Argentina
Keynote lecture, First Meeting of the Latin-American Chapter of the IADR, Mar del Plata, Argentina
Keynote oration, International Congress on Oral Cancer, Crete, Greece
Symposium on Clinical applications in Molecular Biology, International Congress on Oral Cancer, Crete, Greece
Keynote lecture, Oral and Medicine Pathology, IADR and AADR meeting, Baltimore, MD
MD Anderson Cancer Center, Austin, TX
Institute of Materials Science, University of Connecticut, Storrs, CT
Van Andel Research Institute, Grand Rapids, MI
Symposium on MAP kinases and Cancer, CNIO, Madrid, Spain
University of Michigan, Ann Arbor, MI

Symposia Organized:

1995	Workshop on Signaling through G proteins, NIH
1996	Workshop on Signal Transduction from the Membrane to the Nucleus, NIH
1996	Third Annual Signal Transduction Therapy Conference, San Diego, California
1996	Symposium on Regulation of Protein Kinases Involved in Cell Division, Congress of the Pan American Association of Biochemistry and Molecular Biology, Pucon, Chile
1998	Workshop on G proteins, 10th International Conference on Second Messengers & Phosphoproteins, Jerusalem, Israel
1999	Workshop on "Head and Neck Cancer Priority Setting", organizing committee, NIH
1999	Keystone Winter Symposia, "Oncogene Networks" and Session on "Cell Surface Receptors"
2002	Workshop on Exchange factors, Juan March Foundation, Madrid, Spain
2002	Symposium, Frontiers in Molecular Mechanisms in Cancer, Strategies and Application, Santander, Spain
2002	NCI, NIDCD, NIDCR, Trans-NIH Squamous Carcinogenesis Retreat
2002	International Oral Cancer Tissue Array Initiative, Organizing Meeting, NIDCR
2004	Tva-Animal Models Meeting, Bethesda, MD
2005	Advisory Organizing Committee, 10th International Congress on Oral Cancer (ICOOC), Crete, Greece
2006	"Oral Cancer", Naresuan University, Phitsanulok, Thailand
2006	Organizing Committee, "Workshop on Biology and Treatment of Malignant Salivary Gland Cancers", NIH, Bethesda, MD
2006	Elected, Co-chair, Gordon Research Conference, "Phosphorylation & G-Protein Mediated Signaling Networks", 2008
2007	Advisory Committee, International Association of Oral Oncology, 1st World Congress, Amsterdam
2008	Co-chair, Gordon Research Conference, "Phosphorylation & G-Protein Mediated Signaling Networks", Biddeford, Maine
2008	Organizing Committee, International Conference on Frontiers of Dental and Craniofacial Research, Beijing, China.
2008	Program Committee, 7th International Conference on Head and Neck Cancer, San Francisco, CA.
2008	Program Committee, Workshop on Salivary Gland Tumor Research: Current Status and Future Directions. Bethesda, MD.
2009	Scientific Advisory Committee, International Oral Oncology Meeting, Toronto, Canada.
2010	Co-Organizer, The First South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2010, Cordoba, Argentina
2011	Scientific Advisory Committee, Cell Signaling Networks 2011, Merida, Yucatan, Mexico
2012	Co-Organizer, The Second South American Spring Symposium in Signal Transduction and Molecular Medicine, SISTAM 2012, Argentina

Intramural Activities outside the NIDCR DIR

1996	Member, Search Committee for SBRS position, LCMB, NCI
1996	Chair, Search Committee for Tenure Track Scientist, NCI-Navy Clinical Oncology Branch
1996	Ad-hoc member, NIH Central Tenure Committee
1998-2000	Chair, Head and Neck Cancer Consortium, NIH
1998-2001	Member, NIH Central Tenure Committee
1999	Member, Search Committee, Director Division of Basic Sciences, NCI
2000	Member, Search Committee, Structural Biology, NIDDK
2000	Member, Grant Review Panel, Division of Basic Science, NCI
2001	Member, Search Committee, Structural Biology, NIDDK
2001	Member, Search Committee, Tenure Track Investigator, NIAID
2001-2004	Member, Steering Committee, NIH-NCI Upper Aerodigestive Track Cancer Intramural Faculty
2002-2003	Chair, Search Committee, Tenure Track Investigator, NIAMS
2002	Member, Search Committee, Structural Biology, NIDDK
2002	Co-Chair, Inter-Institute Head and Neck Cancer Consortium, NIH
2002	Member, Search Committee, Laboratory Chief, NCI
2002	Member, Search Committee, Deputy Director, DBS Frederick, NCI
2003	Member, Search Committee, Tenure Track Investigator, NHLBI
2003	Member, NIH Ethics Committee, review panel
2003-present	Member, NIDCD, Title 42 Standing Committee
2004	Member, Search Committee, Tenure Track Investigator, NIA
2004	Ad-Hoc Member, NIAID, Tenure Review Panel
2004	Member, Search Committee, Tenure Track Investigator, NIA
2005	Ad-Hoc Member, NCI CCR Tenure Review Panel, NCI
2005	Ad-Hoc member, NIH Central Tenure Committee
2005	Member, Search Committee, Tenure Track Investigator, NIDDK
2005	Member, Search Committee, Laboratory Chief, DBS Frederick, NCI
2005	Member, Search Committee, Program Director, DBS Frederick, NCI
2006	Ad-Hoc Member, NCI CCR Tenure Review Panel, NCI, 2 reviews
2006	Ad-Hoc member, NIH Central Tenure Committee, 2 Tenure Track Reviews
2006	Member, Search Committee, Tenure Track Investigator, NIMH
2006	Member, Search Committee, Director, CCR, NCI
2006	Member, Search Committee, Tenure and Tenure Track investigator, NEI
2006	Co-chair, Group 1, Trans-NIH Intramural Research Initiatives
2007	Ad-Hoc Member, NIH Central Tenure Committee
2007	Ad-Hoc Member, NHGRI, Tenure Review Panel
2007	Member, Member, Search Committee, Scientific Director of the Center for Cancer Research, NCI
2007	Member, Search Committee, Tenure Track Investigator, Laboratory of Cellular and Molecular Biology, NCI
2007	Ad-Hoc member, NIH Central Tenure Committee, Tenure Track review
2008-2009	Member, Search Committee, Tenure Track investigator, NHGRI
2008	Member, Search Committee, Tenure Track investigator, NICHD

2009	Member, Search Committee, Tenure Track investigator, NCI
2009	Member, Search Committee, NIH Stadtman Investigator
2010	Member, Search Committee, 2 Tenure Track investigators, NCI
2010	Member, Search Committee, NIH Stadtman Investigator
2010	Member, Reviewing Committee, Intramural NIH Induced Pluripotent Stem Cell Center (NiPSCC) Award Program
2011	Chair, Cancer Biology Search Committee, NIH Stadtman Investigator (2011)

Activities within NIDCR DIR

1995	Member, Search Committee for Chief, Gene Targeting Facility, NIDR
1995	Member, Search Committee for Tenure Track Scientist, Smell and Taste Unit, NIDR
1995-1997	Member, Gene Targeting Facility Oversight Committee, NIDR
1995-1996	Member, Sequencing Core Facility Oversight Committee, NIDR
1996	Member, Search Committee for Laboratory Chief, NAB, NIDR
1997	Member, Search Committee for Dental Officer, NIDR
1997-2006	Member, NIDCR Administrative Oversight Committee
1997-2006	Member, NIDCR Tenure and Promotion Committee
2002-2003	Member, Search Committee, Tenure Track Investigator, NIDCR
2005	Member, Search Committee, Tenure Track Investigator, NIDCR
2006	Member, two Search Committees, Tenure Track Investigator, NIDCR
2006-present	Co-chair, Craniofacial Tissue Remodeling Initiative, NIDCR
2007	Member, Search Committee, Deputy Director, IRP, NIDCR
2007	Member, Search Committee, Associate Director for Management, NIDCR
2008-2009	Member, Search Committee, Clinical Director, NIDCR Organizing Committee, Workshop on salivary Gland Tumor Research: Current Status and Future Directions, Bethesda

Current Clinical Protocols

- NCT01195922, A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer. NIDCR/NCI/NIDCD/MUSC.
  PI: Gutkind J.S. 2010.
- T-D-0024, The Molecular Anatomy of Oral Wound Healing. NIDCR.
  PI: Gutkind J.S. 2010.
  PI: Marur S. Co-Investigator: Gutkind J.S. 2009.
- NCT01051791, Phase II Study of RAD001 in Head and Neck Cancer. U. Pittsburgh.
  PI: Gibson M. Laboratory Chair: Gutkind J.S. University of Pittsburgh. 2010.
- NCT00882583, A Study of Dasatinib, Cetuximab and Radiation with or without Cisplatin in Head and Neck Squamous Cell Carcinoma. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
  PI: Marur S. Co-Investigator: Gutkind J.S. 2010.

Invention Reports and Patents:

- 5,384,243, issued January 24, 1995. J. Silvio Gutkind and Keith C. Robbins: Method for screening an agent for its ability to prevent cell transformation.
- Use of mTOR inhibitors for oral cancer chemoprevention. Filed, 2008.
- DSG3 as a Biomarker for the Detection of Metastasis. Filed, 2009.

Ph.D. Thesis Directed:

G.M. Kalinec, Ph.D., University of Cordoba, Cordoba, Argentina, 1992
M. Chiariello, M.D. Ph.D., University of Naples, Naples, Italy, 1999. Co-director
L.M. Laguinge, Ph.D., Catholic University of Cordoba, Cordoba, Argentina, 2000
C. Leethanakul, D.D.S., Ph.D., Chulalongkorn University, Bangkok, Thailand, 2000
P. Amornphimoltham, D.D.S., Ph.D., University of Maryland, 2006
M.D. Castellone, M.D., Ph.D., University of Naples, Naples, Italy, 2005. Co-director
K. Leelahavanichkul , D.D.S. Ph.D., Tammasat University, Bangkok, Thailand, 2011

Selected publications, signal transduction research:

1. Crespo P., Xu N., Simonds W.F., and Gutkind J.S. Ras-dependent activation of MAP kinase pathway mediated by G-protein βγ subunits. *Nature,* **369:**418-420, 1994.
2. Coso O., Chiariello M., Yu J.-C., Crespo P., Teramoto, H., Xu N., Miki T., and Gutkind J.S. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK (SAPK) signaling pathway. *Cell,* **81:**1137-1148, 1995.
3. Lopez-Ilasaca M., Crespo P., Pellici P.G., Gutkind J.S.*, and Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase γ. *Science,* **275:**394-397, 1997.
4. Crespo P., Schuebel K.E., Ostrom A.A., Gutkind J.S., and Bustelo X.R. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the *vav* proto-oncogene product. *Nature,* **385:**169-172, 1997.
5. Chiariello M., Marinissen M.J., and Gutkind J.S. Regulation of c-*myc* expression by PDGF through Rho GTPases. *Nature Cell Biol.*, **3**:580-586, 2001.
6. Montaner S., Sodhi A., Molinolo A., Bugge T.H., Sawai E.T., He Y., Li Y., Ray P.E., and Gutkind J.S. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. *Cancer Cell*, **3**:23-36, 2003.
7. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., and Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a novel Gs-axin-β-catenin signaling axis. *Science,* **310**:1504-1510, 2005.
8. Gavard J. and Gutkind J.S. VEGF controls endothelial cell permeability by promoting the β-arrestin-dependent endocytosis of VE-cadherin. *Nature Cell. Biol*., **11**:1223-1234, 2006.

9. Martin D., Galisteo R., Molinolo A.A., Wetzker R., Hirsch E., and Gutkind J.S. PI3Kγ mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. *Cancer Cell,* **19:** 805-813, 2011.
10. Yagi H., Tan W., Dillenburg-Pilla P., Armando S., Amornphimoltham P., Simaan M., Weigert R., Molinolo A.A., Bouvier M., and Gutkind J.S. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. *Science Signaling*, **4**:ra60, 2011.

Selected publications, oral cancer research:

1. Leethanakul C., Patel V., Gillespie J., Pallante M., Ensley J.F., Liotta L.A., Emmert-Buck M., and Gutkind J.S. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. *Oncogene,* **19**:3220-3224, 2000.
2. Amornphimoltham P., Sriuranpong V., Patel V., Benavides F., Conti C.J., Sauk J., Sausville E.A., Molinolo A.A., and Gutkind J.S., Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01, *Clin. Cancer Research,* **10**:4029-37, 2004.
3. Vitale-Cross L., Amornphimoltham P., Fisher G., Molinolo A.A., and Gutkind J.S. Conditional expression of K-ras in an epithelial compartment that includes the stem-cells is sufficient to promote squamous cell carcinogenesis. *Cancer Res.,* **64**:8804-8807, 2004.
4. Amornphimoltham P., Patel V., Sodhi A., Nikitakis N.G., Sauk J.J., Sausville E.A., Molinolo A.A., and Gutkind J.S. mTOR, a molecular target in squamous cell carcinomas of the head and neck. *Cancer Research,* **65**:9953-9961, 2005.
5. Basile J.R., Castilho R.M., Williams V.P., and Gutkind JS. Semaphorin4D provides a link between anon guidance processes and tumor-induced angiogenesis, *Proc. Natl. Acad. Sci. U.S.A.* **103**:9017-9022, 2006.
6. Molinolo A.A., Hewitt S., Amornphimoltham P., Keelawat S., Rangdaeng S., Meneses García A., Raimondi A.R., Jufe R., Itoiz M., Gao Y., Saranath D., Kaleebi G.S., Yoo G.H., Leak L., Myers E.M., Shintani S., Wong D., Massey H.D., Yeudall W.A., Lonardo F., Ensley J., and Gutkind J.S. Dissecting the Akt/mTOR signaling network: Emerging results from the Head and Neck Cancer Tissue Array Initiative. *Clinical Cancer Research*, **13**:4964-4973, 2007.
7. Amornphimoltham P., Patel V., Leelahavanichkul K., Abraham R.T, and Gutkind J.S. A retro-inhibition approach reveals a tumor cell-autonomous therapeutic response to rapamycin in head and neck squamous cell carcinomas. *Cancer Research*, **68**:1144-1153, 2008.
8. Czerninski R., Amornphimoltham P., Patel V., Molinolo A.A., and Gutkind J.S. Targeting mTOR by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. *Cancer Prevention Research*, **2**:27-36, 2009.
9. Castilho R.M, Squarize C.H., Chodosh L.A., Williams B.O., and Gutkind J.S. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. *Cell Stem Cell*, **5**:279-289, 2009.
10. Patel V., Marsh C.A., Dorsam R.T., Masedunskas A., Amornphimoltham P., Nathan C.O., Singh B., Weigert R., Molinolo A.A., and Gutkind J.S. Decreased

lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. *Cancer Research*, **71**:7103-7112, 2011.

Bibliography
(Total 360 publications: 303 peer-reviewed studies, 26 review articles, 31 book chapters)

Peer Reviewed Research Articles

1. Gutkind J.S. and Enero M.A. Noradrenaline uptake inhibitors counteract the cardiovascular effects of clonidine but not those of guanabenz. *Commun. Biol.*, **1:**319-326, 1983.
2. Gutkind J.S. and Enero M.A. Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia. *Naunyn Schmiedeberg's Arch. Pharmacol.*, **327:**189-192, 1984.
3. Gutkind J.S., Bognar I., and Enero M.A. Pharmacological characterization of guanabenz, clonidine-like anti-hypertensive drug. *J. Cardiol. (Argentina)*, **53:**145-147, 1985.
4. Gutkind J.S., Kazanietz M.G., and Enero M.A. Cardiovascular effects of alpha-adrenergic drugs: differences between clonidine and guanabenz. *Naunyn Schmiedeberg's Arch. Pharmacol.*, **332:**370-375, 1986.
5. Gutkind J.S. and Enero M.A. Effects of desipramine on the cardiovascular responses to clonidine and guanabenz. *Hypertension*, **8:**184-186, 1986.
6. Kazanietz M.G., Gutkind J.S., and Enero M.A. Interaction between β_2- and α_2-adrenoceptor responses in the vascular system: effect of clenbuterol. *Eur. J. Pharmacol.*, **130:**119-124, 1987.
7. Castren E., Kurihara M., Gutkind J.S., and Saavedra J.M. Specific angiotensin II binding sites in the rat stellate and superior cervical ganglion. *Brain Research*, **422:**347-351, 1987.
8. Gutkind J.S. and Enero M.A. Different pharmacological interaction of clonidine and guanabenz with antidepressive drugs. *Clin. Exper. Hypertension*, **A9:**1531-1547, 1987.
9. Gutkind J.S., Kurihara M., Castren E., and Saavedra J.M. Atrial natriuretic peptide receptors in sympathetic ganglia: Biochemical response and alterations in genetically hypertensive rats. *Biochem. Biophys. Res. Commun.*, **149:**65-72, 1987.
10. Kurihara M., Castren E., Gutkind J.S., and Saavedra J.M. Lower number of atrial natriuretic peptide receptors in thymocytes and spleen cells of spontaneously hypertensive rats. *Biochem. Biophys. Res. Commun.*, **149:**1132-1140, 1987.
11. Saito K., Gutkind J.S., and Saavedra J.M. Angiotensin II binding sites in the conduction system of the rat heart. *Am. J. Physiol.*, **253:** (Heart Circ. Physiol. 22), H1618-H1622, 1987.
12. Gutkind J.S., Kurihara M., Castren E., and Saavedra J.M. Increased concentration of angiotensin II binding sites in selected brain areas of spontaneously hypertensive rats. J. *Hypertension*, **6:**79-84, 1988.
13. Kurihara M., Gutkind J.S., Saavedra J.M. Alteration of atrial natriuretic peptide binding sites in spontaneously hypertensive rats. *Am. J. Hypertension*, **1:**12S-14S, 1988.

14. Kurihara M., Castren E., Gutkind J.S., Saito K., and Saavedra J.M. Characterization of β-adrenergic receptors in sections from human blood lymphocyte pellets by quantitative auto-radiography. *Biological Psychiatry,* **23:**746-749, 1988.
15. Nazarali A.J., Gutkind J.S., and Saavedra J.M. Regulation of angiotensin II binding sites in discrete rat brain nuclei after water deprivation. *Cell. Molec. Neurobiol.,* **7:**447-455, 1988.
16. Gutkind J.S., Castren E., and Saavedra J.M. Decreased angiotensin II binding in the anterior pituitary gland of spontaneously hypertensive rats. *Life Science,* **43:**441-451, 1988.
17. Gutkind J.S., Kurihara M., Castren E., and Saavedra J.M. Autoradiographic quantification of vasoactive intestinal peptide binding sites in sections from human blood lymphocytes pellets. *Neuropsychopharmacol*., **1:**251-255, 1988.
18. Gutkind J.S., Kurihara M., and Saavedra J.M. Increased angiotensin II receptors in brain nuclei of DOCA-salt hypertensive rats. *Am. J. Physiol.,* **255:** (Heart Circ. Physiol. 24), H646-H650, 1988.
19. Nazarali A.J., Gutkind J.S., Correa F.M.A., and Saavedra J.M. Effect of chronic administration of the converting enzyme inhibitor enalapril (MK 421) on brain atrial natriuretic peptide receptors in Wistar-Kyoto and spontaneously hypertensive rats. *Brain Research,* **475:**134-140, 1988.
20. Gutkind J.S., Kazanietz M.G., Armando I., Puyo A., and Enero M.A. Pressor response induced by clenbuterol treatment in immobilized normotensive rats. *J. Cardiovasc. Pharmacol.,* **13:**793-798, 1989.
21. Kazanietz M.G., Gutkind J.S., Puyo A., Armando I., and Enero, M.A. Further evidence for interaction between vasodilators beta-2-adrenoceptor and vasoconstriction-alpha-2-adrenoceptor mediated responses in maintaining vascular tone in anesthetized rats. *J. Cardiov. Pharmacol.,* **14:**874-880, 1989.
22. Nazarali A.J., Gutkind J.S., Correa F.M.A., and Saavedra J.M. Selective decrease of angiotensin II receptors in the subfornical organ of spontaneously hypertensive rats after chronic treatment with a converting enzyme inhibitor. *Am. J. Physiol.,* **256:**H1609-H1614, 1989.
23. Nazarali A.J., Gutkind J.S., and Saavedra J.M. Calibration of [^{125}I]-polymer standards with [^{125}I]-brain paste standards for use in quantitative receptor autoradiography. *J. Neurosc. Methods,* **30:**247-253, 1989.
24. Sugita K., Gutkind J.S., Katamine S., and Robbins K.C. The actin domain of Gardner-Rasheed feline sarcoma virus inhibits kinase and transforming activities. *J. Virology,* **63:**1715-1720, 1989.
25. Notario V., Gutkind J.S., Imaizumi M., Katamine S., and Robbins K.C. Expression of the *fgr* proto-oncogene product as a function of myelomonocytic cell maturation. *J. Cell Biol*., **109:**3129-3136, 1989.
26. Gutkind J.S. and Robbins K.C.: Mobilization of the c-*fgr* protein-tyrosine kinase as a consequence of neutrophil activation. *Proc. Natl. Acad. of Sci. USA,* **86:**8783-8787, 1989.
27. Gutkind J.S., Lacal P.M., and Robbins K.C. Thrombin-dependent association of phosphatidylinositol-3 kinase with p60$^{c\text{-}src}$ and p59^{fyn} in human platelets, *Mol. Cell. Biol.,* **10:**3806-3809, 1990.

28. Benhamou M., Gutkind J.S., Robbins K.C., and Siraganian R.P. Tyrosine phosphorylation coupled to IgE receptor-mediated signal transduction and histamine release. *Proc. Natl. Acad. Sci. USA,* **87:**5327-5330, 1990.
29. Vukicevic S., Paralkar V.M., Cunningham N.S., Gutkind J.S., and Reddi A.H. Autoradiographic localization of osteogenin binding sites in cartilage and bone during rat embryonic development. *Dev. Biol.,* **140:**209-214, 1990.
30. Heidaran M.A., Pierce J.H., Lombardi D., Ruggiero M., Gutkind J.S., Matsui T., and Aaronson S.A. Deletion or substitution within the α PDGF receptor kinase insert domain: effects on functional coupling with intracellular signaling pathways. *Mol. Cell. Biol.*, **11:**134-142, 1991.
31. Yu, J.-C., Heidaran M.A., Pierce J.H., Gutkind J.S., Lombardi D., Ruggiero M., and Aaronson S.A. Tyrosine mutations within the αPDGF kinase insert domain abrogate receptor-associated PI-3 kinase activity without affecting mitogenic or chemotactic signal transduction. *Mol. Cell. Biol.,* **11:**3780-3785, 1991.
32. Gutkind J.S., Link D.C., Katamine S., Lacal P., Miki T., Ley T.J., and Robbins K.C. A novel c-*fgr* exon utilized in Epstein-Barr virus infected B-lymphocytes but not normal monocytes. *Mol. Cell. Biol.,* **11:**1505-1507, 1991.
33. Gusovsky F. and Gutkind J.S.: Selective effect of activation of protein kinase-C isoenzymes on cAMP accumulation. *Mol. Pharmacol.,* **39:**124-129, 1991.
34. Gutkind J.S., Novotny E., Brann M.R., and Robbins K.C. Muscarinic acetylcholine receptor subtypes as agonist dependent oncogenes. *Proc. Natl. Acad. Sci. USA,* **88:**4703-4707, 1991.
35. Hermouet S., Merendino J. Jr., Gutkind J.S., and Spiegel A.M. Activating and inactivating mutations of $G_{\alpha i2}$ have opposite effects on proliferation of NIH 3T3 cells. *Proc. Natl. Acad. Sci. USA,* **88:**10455-10459, 1991.
36. Sartor O., Moriuchi R., Sameshima J., Severino M., Gutkind J.S., and Robbins K.C. Diverse biologic properties imparted by the c-*fgr* proto-oncogene. *J. Biol. Chem.,* **267:**3460-3465, 1992.
37. Volker S., Benhamou M., Gutkind J.S., Robbins K.C., and Siraganian R.P. Fc,RI-induced protein tyrosine phosphorylation of pp72 in rat basophilic leukemia cells (RBL-2H3): Evidence for a novel signal transduction pathway unrelated to G protein activation and phosphatidylinositol hydrolysis. *J. Biol. Chem.,* **267:**5434-5441, 1992.
38. Thompson P.A., Gutkind J.S., Robbins K.C., Ledbetter J.A., and Bolen J.B. Identification of distinct populations of PI-3 kinase following T cell activation. *Oncogene,* **7:**719-725, 1992.
39. Link D.C., Gutkind J.S., Robbins K.C., and Ley T.J. Characterization of the 5' untranslated region of the human c-*fgr* gene and identification of the major myelomonocytic c-*fgr* promoter. *Oncogene,* **7:**877-884, 1992.
40. Kalinec G., Nazarali A.J., Hermouet S., Xu N., and Gutkind J.S. Mutated α subunit of the G_q protein induces malignant transformation in NIH 3T3 cells. *Mol. Cell. Biol.*, **12:**4687-4693, 1992.
41. Gutkind J.S. and Robbins K.C. Activation of transforming G protein-coupled receptors induces rapid tyrosine phosphorylation of cellular proteins, including $p125^{FAK}$ and the p130 v-*src* substrate. *Biochem. Biophys. Res. Commun.*, **188:**155-161, 1992.

42. Wang L.-M., Keegan A.D., Paul W.E., Heidaran M.A., Gutkind J.S., and Pierce J.H. IL-4 activates a distinct signal transduction cascade from IL-3 in factor dependent myeloid cells. *EMBO J.,* **11:**4899-1908, 1992.
43. Stephens E.V., Kalinec G., Brann M.R., and Gutkind J.S. Transforming G protein-coupled receptors transduce potent mitogenic signals in NIH 3T3 cells independent of cAMP-inhibition or conventional protein kinase C. *Oncogene,* **8:**19-26, 1993.
44. Wang L.-M., Keegan A.D., Li W., Lienhard G.E., Pacini S., Gutkind J.S., Myers M.G., Sun X.-J, White M.F., Aaronson S.A., Paul W.E., and Pierce J.H. Common elements in IL-4 and insulin signaling pathways in factor dependent hematopoietic cells. *Proc. Natl. Acad. Sci. USA* **90:**4032-4036, 1993.
45. Xu N., Bradley L., Ambdukar I., and Gutkind J.S. A mutant α subunit of G_{12} potentiates the eicosanoid pathway and is highly oncogenic in NIH 3T3 cells. *Proc. Natl. Acad. Sci. USA,* **90:**6741-6745, 1993.
46. Xu N., McCormick F., and Gutkind J.S. The non-catalytic domain of *ras*-GAP inhibits transformation induced by G protein coupled receptors. *Oncogene,* **9:**597-602, 1994.
47. Xu N., Voyno-Yasenetskaya T., and Gutkind J.S. Potent transforming activity of the $G_{13}\alpha$ subunit defines a novel family of oncogenes. *Biochem. Biophys. Res. Commun.,* **201:**603-609, 1994.
48. Calderon S.N., Izenwasser S., Heller B., Gutkind J.S., Mattson M., Su T.-P., and Newman A.H. Novel 1-phenylcycloalkanecarboxylic acid derivatives are potent and selective $sigma_1$ ligands. *J. Med. Chem.,* **37:**2285-2291, 1994.
49. Crespo P., Xu N., Daniotti J.L, Rapp U.R, and Gutkind J.S. Signaling through transforming G protein-coupled receptors in NIH 3T3 cells involves c-Raf activation: Evidence for a protein kinase C independent pathway. *J. Biol Chem.,* **269:**21103-21109, 1994.
50. Crespo P., Xu N., Simonds W.F., and Gutkind J.S. Ras-dependent activation of MAP kinase pathway mediated by G-protein βγ subunits. *Nature,* **369:**418-420, 1994.
51. Yu J-C., Gutkind J.S., Mahadevan D., Li W., Meyers K.A., Pierce J.H., and Heidaran M.A. Biological function of PDGF-induced PI-3 kinase activity: Its role in αPDGF receptor-mediated mitogenic signaling. *J. Cell Biol*., **127:**479-488, 1994.
52. Coso O., Chiariello M., Kalinec G., Kyriakis J., Woodgett J., and Gutkind J.S. Transforming G protein-coupled receptors potently activate JNK (SAPK): evidence for a divergence from the tyrosine-kinase signaling pathway. *J. Biol. Chem***.,** **270:**5620-5624, 1995.
53. Crespo P., Cachero T.G., Xu N., and Gutkind J.S. Dual effect of β-adrenergic receptors on MAP kinase: Evidence for a βγ-dependent activation and a $G\alpha_s$-cAMP-mediated inhibition. *J. Biol. Chem.,* **270:**25259-25265, 1995.
54. Crespo P., Mischak H., and Gutkind J.S. Overexpression of mammalian protein kinase C-ζ does not affect the growth characteristics of NIH 3T3 cells. *Biochem. Biophys. Res. Commun.,* **213:**266-272, 1995.
55. Mahadevan D., Thaki N., Singh J., McPhie P., Zangrilli D., Wang L.-M., Guerrero C., LeVine H., Humblet C., Saldanha J., Gutkind J.S., and Haske T. Structural studies on the PH domains of Dbl, Sos1, IRS-1 and βARK1 and their differential binding to Gβγ subunits. *Biochemistry J.* **34:**9111-9117, 1995.

56. Miyamoto S., Teramoto H., Coso O., Gutkind J.S., Burbelo P.D., Akiyama S.K., and Yamada K.M. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. *J. Cell. Biol.,* **131:**791-805, 1995.
57. Coso O., Chiariello M., Yu J.-C., Crespo P., Teramoto, H., Xu N., Miki T., and Gutkind J.S. The small GTP-binding proteins Rac1 and Cdc42 regulate the activity of the JNK (SAPK) signaling pathway. *Cell,* **81:**1137-1148, 1995.
58. Coso O.A., Teramoto H., Simonds W.F., and Gutkind J.S. Signaling from G protein-coupled receptors to JNK/SPK involves βγ subunits of heterotrimeric G proteins acting on a Ras and Rac1-dependent pathway. *J. Biol. Chem.,* **271:**3963-3966, 1996.
59. Xu N., Coso O.A., Mahadevan D., De Blasi A., Goldsmith P.K., Simonds W.F., and Gutkind J.S. The PH domain of Ras-GAP is sufficient for in vitro binding to βγ subunits of heterotrimeric G proteins. *Cell. Mol. Neurobiol.,* **16:**51-59, 1996.
60. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind J.S., and Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. *Nature,* **381:**800- 803, 1996.
61. Zhang S., Coso O.A., Collins R., Gutkind J.S., and Simonds W.F. A carboxyl-terminal mutant of the G-protein β subunit deficient in the activation of phospholipase C-β. *J. Biol. Chem.,* **271:**20208-20211, 1996.
62. Kieser A., Adler H.S., Seitz T., Crespo P., Gutkind J.S., Kolch W., and Mischak H. Protein Kinase Cζ inhibits cellular transformation by upregulating *jun*-B and *egr*-1 expression. *Genes and Development,* **10:**1455-1466, 1996.
63. Crespo P., Bustelo X.R., Aaronson D.S., Coso O.A., Lopez-Barahona M., Barbacid M., and Gutkind J.S. Rac-1 dependent stimulation of the JNK/SAPK pathway by Vav. *Oncogene,* **13:**455-460, 1996.
64. Sundaresan M., Yu Z.-X., Ferrans V.J., Sulciner D.J., Gutkind J.S., Irani K., Goldschmidt-Clermont P.J., and Finkel T. Regulation of Reactive oxygen species generation in fibroblast by Rac1. *Biochem. J.,* **318:**379-382, 1996.
65. Calderon S.N., Bertha C.M., Gutkind J.S., Xu H., Partilla J.S., Rothman R.B., and Rice K. C. Probes for Narcotic receptor mediated phenomena. Synthesis and characterization of optically pure [^{3}H](+)-4-[(α*R*)-α -((2*S*,5*R*)-4-Propyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]- N,Ndiethylbenzamide, [^{3}H]SNC121, a novel high affinity and selective ligand for delta opioid receptors. *J. Labelled Comp. Radiopharm*. **38:**347-350, 1996.
66. Teramoto H., Crespo P., Coso O.A., Igishi T., Xu N., and Gutkind J.S. The small GTP-binding protein Rho activates JNK/SAPK in human kidney 293T cells: Evidence for a Pak-independent signaling pathway. *J. Biol. Chem.,* **271:**25731-25734, 1996.
67. Teramoto H., Coso O.A., Miyata H., Igishi T., and Gutkind J.S. Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the JNK/SAPK pathway: A role for MLK3/PTK1, a novel member of the mixed-lineage kinase family. *J. Biol. Chem*., **271:**27225-27228, 1996.
68. Zhang S., Coso O.A., Lee C., Gutkind J.S., and Simonds W.F. Selective activation of effector pathways by brain-specific G protein β5. *J. Biol. Chem.,* **271:**33575-33579, 1996.
69. Miyamoto S., Teramoto H., Gutkind J.S., and Yamada K.M. Integrins can synergize with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase

activation: Roles of integrin aggregation and occupancy of receptors. *J. Cell Biol.,* **135:**1633-1642, 1996.

70. Herrera L., Hinrichs M.V., Frías J., Gutkind J.S., and Olate J. Dual transduction signaling by a xenopus muscarinic receptor: Adenylyl cyclase inhibition and MAPK activation. *J. Cell. Biochem.,* **64:**1-8, 1997.
71. Lopez-Ilasaca M., Crespo P., Pellici P.G., Gutkind J.S.*, and Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase γ. *Science,* **275:**394-397, 1997.
72. Gordeladze J.O., Hovik K.E., Merendino J.J., Hermouet S., Gutkind J.S., and Accili D. Effect of activating and inactivating mutations of G_s- and G_{i2}-alpha protein subunits on growth and differentiation of 3T3-L1 preadipocytes. *J. Cell. Biochem.,* **64:**242-257, 1997.
73. Crespo P., Schuebel K.E., Ostrom A.A., Gutkind J.S., and Bustelo X.R. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the *vav* proto-oncogene product. *Nature,* **385:**169-172, 1997.
74. Gutkind J.S., Crespo P., Xu N., Teramoto H., and Coso O.A. The pathway connecting m2 receptors to the nucleus involves small GTP-binding proteins acting on divergent MAP kinase cascades. *Life Sci.,* **60:**999-1006, 1997.
75. Teramoto H., Salem P., Robbins K.C., Bustelo X., and Gutkind J.S. Tyrosine phosphorylation of the *vav* proto-oncogene product links FcεRI to the Rac1-JNK pathway. *J. Biol. Chem.,* **272:**10751-10755, 1997.
76. Lopez-Ilasaca M., Li W., Uren A., Yu J.-C., Kazlauskas A., Gutkind J.S., and Heidaran M.A. Requirement of phosphatidylinositol-3 kinase for activation of JNK/SAPKs by PDGF-β receptors. *Biochem. Biophys. Res. Commun.,* **232:**273-277, 1997.
77. Buckbinder L., Velasco-Miguel S., Xu N., Chen Y., Talbott R., Gelbert L., Gao J., Seizinger B.R., Gutkind J.S., and Kley N. Inhibition of G protein-mediated activation of the MAP kinase pathway by a novel target of the p53 tumor suppressor. *Proc. Natl. Acad Sci. U.S.A.,* **94:**7868-7872, 1997.
78. Coso O.A., Montaner S., Fromm C., Teramoto H., Prywes R., Lacal J.C. and Gutkind J.S. Signaling from G protein-coupled receptors to the c-jun promoter involves the MEF2 transcription factor: evidence for a Novel JNK-independent pathway. *J. Biol. Chem.,* **272:**20691-20697, 1997.
79. Uren A., Jakus J., Font de Mora J., Yeudall A., Santos E., Gutkind J.S., and Heidaran M.A. Carboxy-terminal domain of p27Kip1 activates cdc2. *J. Biol. Chem.,* **272:**2669-2672, 1997.
80. Fromm C., Coso O.A., Montaner S., Xu N., and Gutkind J.S. The small GTP-binding protein Rho links G protein-coupled receptors and $G\alpha_{12}$ to the serum response element and to cellular transformation. *Proc. Natl. Acad. Sci. U.S.A.,* **94:**10098-10103, 1997.
81. Jin D.-Y, Teramoto H., Giam L.-Z., Chun R.F., Gutkind J.S., and Jeang K.-T. A human suppressor of JNK activation by TNFα. *J. Biol. Chem.,* **272:**25816-25823, 1997.
82. Liu J.L, Blakesley V.A., Gutkind J.S., and Le Roith D. The constitutively active mutant of $G\alpha_{13}$ transforms mouse fibroblast cells deficient in insulin-growth factor-I receptor. *J. Biol. Chem.,* **272:**29438-29441, 1997.
83. Bustelo X.R., Crespo P., Lopez-Barahona M., Gutkind J.S., and Barbacid M. Cbl-b, a member of the sli-1/c-cbl protein family inhibits Vav-mediated c-Jun N-terminal kinase activation. *Oncogene,* **15:**2511-2520, 1997.

84. Alimandi M., Heidaran M.A., Gutkind J.S., Zhang J., Ellmore N., Kazalauskas V.M., Pierce J.H., and Li Q. PLC-γ activation is required for PDGF-βR-mediated mitogenesis and monocytic differentiation in myeloid progenitor cells. *Oncogene,* **15:**585-593, 1997.
85. Bais C., Santomasso B., Coso O.A., Arvanitakis L., Raaka E., Gutkind J.S., Asch A., Cesarman E., Gershengorn M.C., and Mesri E. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor is a viral oncogene and angiogenesis activator. *Nature,* **391:**86-89, 1998.
86. Lopez-Ilasaca M., Gutkind J.S., and Wetzker R. Phosphoinositide 3-kinase γ is a mediator of Gβγ-dependent Jun kinase activation. *J. Biol. Chem.,* **273:**2505-2508, 1998.
87. Jones T.L.Z. and Gutkind J.S. $G\alpha_{12}$ requires acylation for its transforming activity. *Biochemistry,* **37:**3196-3202, 1998.
88. Igishi T. and Gutkind J.S. Tyrosine kinases of the Src family participate in signaling to MAP kinase from both Gq and Gi-coupled receptors. *Biochem. Biophys. Res. Commun.,* **244:**5-10, 1998.
89. Rubino D., Driggers P., Arbit D., Kemp L., Miller B., Coso O., Pagliai K., Gray K., Gutkind J.S. and Segars J. Characterization of Brx, a novel DBL family member that modulates estrogen receptor action. *Oncogene,* **16:**2513-2526, 1998.
90. Chiariello M., Visconti R., Carlomagno F., Melillo R.M., Bucci C., de Franciscis V., Fox G.M., Jing S., Coso O.A., Gutkind J.S., Fusco A., and Santoro M. Signaling of the Ret receptor tyrosine kinase through the JNK: evidence for a divergence of the ERKs and JNKs pathways induced by Ret. *Oncogene,* **16:**2435-2447, 1998.
91. Zohar M., Teramoto H., Katz B.-Z., Yamada K.M., and Gutkind J.S. Effector domain mutants of Rho dissociate cytoskeletal changes from nuclear signaling and cellular transformation. *Oncogene,* **17:**991-998, 1998.
92. Murga C., Laguinge L., Wetzker R., Cuadrado A., and Gutkind J.S. Activation of Akt/PKB by G protein-coupled receptors: A role for α and βγ subunits of heterotrimeric G proteins acting through PI3Kγ. *J. Biol. Chem.,* **273:**19080-19085, 1998.
93. Deb T.B., Wong L., Salomon D.S., Zhou G.C., Dixon J.E., Gutkind J.S., Thompson S.A., and Johnson G.R. A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors - A specific role for SHP-2 in MAPK, but not c-jun amino-terminal kinase activation. *J. Biol. Chem.,* **273:**16643-16646, 1998.
94. Crespo P., de Mora J.F., Aaronson D.S., Santos E., and Gutkind J.S.: Transforming G protein-coupled receptors block insulin and ras-induced adipocytic differentiation in 3T3-L1 cells: Evidence for a PKC and MAP kinase independent pathway. *Biochem. Biophys. Res. Commun.,* **245:**554-561, 1998.
95. Okubo Y., Blakesley V.A., Stannard B., Gutkind J.S., and Le Roith D. Insulin-like growth factor-I inhibits the stress-activated protein kinase/c-Jun N-terminal kinase. *J. Biol. Chem.,* **273:**25961-25966, 1998.
96. Burstein E.S., Hesterberg D.J., Gutkind J.S., Brann M.R., Currier E.A., and Messier T.L. The ras-related GTPase rac1 regulates a proliferative pathway selectively utilized by G-protein coupled receptors. *Oncogene,* **17:**1617-1623, 1998.
97. Patel V., Senderowicz A.M., Pinto D., Ensley J., Igishi T., Sausville E.A., and Gutkind J.S. Flavopiridol, a novel CDK inhibitor, suppresses the growth of squamous cell carcinomas by inducing apoptosis. *J. Clin. Invest.,* **102:**1674-1681, 1998.

98. Korn I., Gutkind J.S., Srinivasan N., Blundell T.L., Allende C.C, and Allende J.E. Interactions of protein kinase CK2 subunits. Interactions of protein kinase CK2 subunits. *Mol. Cell. Biochem.,* **191:**75-83, 1999.
99. Janulis M., Silberman S., Ambegaokar A., Gutkind J.S., and Schultz R.M. Role of mitogen-activated protein kinases and c-Jun/AP-1 trans-activating activity in the regulation of protease mRNAs and the malignant phenotype in NIH 3T3 fibroblasts. *J. Biol. Chem.,* **274:** 801-813, 1999.
100. Fukuhara S., Murga C., Zohar M., Igishi T., and Gutkind J.S. A novel PDZ-domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. *J. Biol. Chem.,* **274:**5868-5879, 1999.
101. Heemskerk F., Zorad S., Xu N., Gutkind J.S., and Saavedra J.M. Characterization of AT2 receptor expression in NIH 3T3 fibroblasts. *Cell. Mol. Neurobiol.,* **19:**277-288, 1999.
102. Soon L., Flechner L., Gutkind J. S., Wang L.-H., Baserga R., Pierce J. H., and Li W. Insulin-like growth factor I synergizes with interleukin 4 for hematopoietic cell proliferation independent of IRS expression. *Mol. Cell. Biol.,* **19:**3816-3824, 1999.
103. Pece S., Chiariello M., Murga C., and Gutkind J.S. Activation of the protein kinase Akt/PKB by the formation of E-cadherin-mediated cell-cell junctions - Evidence for the association of phosphatidylinositol 3-kinase with the E-cadherin adhesion complex. *J. Biol. Chem.,* **274:**19347-19351, 1999.
104. Marinissen M.J., Chiariello M., Pallante M., and Gutkind J.S. A network of mitogen-activated protein kinases links G protein-coupled receptors to the c-*jun* promoter: a role for c-Jun NH2-terminal kinase, p38s, and extracellular signal-regulated kinase 5. *Mol. Cell. Biol.,* **19:**4289-4301, 1999.
105. Scita G., Nordstrom J., Carbone R., Tenca P., Giardina G., Gutkind J.S., Bjarnegård M., Betsholtz C., Di Fiore P.P. EPS8 and E3B1 Transduce signals from Ras to Rac. *Nature* **40:**290-293, 1999.
106. Igishi T., Fukuhara S., Patel V., Katz B.Z., Yamada K.M., and Gutkind J.S. Divergent signaling pathways link FAK to MAP kinase cascades: A role for paxillin in JNK activation. *J. Biol. Chem.,* **274:**30738-30746, 1999.
107. Lerga A., Crespo P., Berciano M., Delgado M.D., Cañelles M., Calés C., Richard C., Ceballos E., Gutierrez P., Ajenjo N., Gutkind J.S., and Leon J. Regulation of c-Myc and Max in megakaryocytic and monocytic-macrophagic differentiation of K562 cells induced by protein kinase C modifiers: c-Myc is down-regulated but does not inhibit differentiation. *Cell Growth Diff.,* **10:**639-654, 1999.
108. Tassi E., Biesova Z., Di Fiore P.P., Gutkind J.S., and Wong W.T. Human JIK, a novel member of the STE20 kinase family that inhibits JNK and is negatively regulated by EGF. *J. Biol. Chem.,* **274:**33287-33295, 1999.
109. Chiang Y.J., Kole H.K., Brown K., Naramura M., Fukuhara S., Hu R.J., Jang I.K., Gutkind J.S., Shevach E., and Gu H. Cbl-b regulates the CD28 dependence of T-cell activation. *Nature,* **403:**216-220, 2000.
110. Shillitoe E.J., May M., Leethanakul C., Patel V., Ensley J.F., Strausberg R.L., and Gutkind J.S. Genome-wide analysis of oral cancer-Early results from the Cancer Genome Anatomy Project. *Oral Oncol.,* **36:**8-16, 2000.
111. Chiariello M., Marinissen M.J, and Gutkind J.S. Multiple MAP kinase signaling pathways connect the Cot oncoprotein to the c-*jun* promoter and to cellular transformation. *Mol. Cell. Biol.,* **20:**1747-1758, 2000.

112. Majidi M., Gutkind J.S., and Lichy J.H. Deletion of the COOH terminus converts the ST5 p70 Protein from an inhibitor of RAS signaling to an activator with transforming activity in NIH-3T3 Cells. *J. Biol. Chem.,* **275:**6560-6565, 2000.
113. Katz B.Z., Zohar M., Teramoto H., Matsumoto K., Gutkind J.S., Lin D.C., Lin S., and Yamada K.M. Tensin can induce JNK and p38 activation. *Biochem. Biophys. Res. Commun*., **272:** 717-720, 2000.
114. Pirone D.M., Fukuhara S., Gutkind J.S., Burbelo P.D. SPECs, Small Binding Proteins for Cdc42. *J. Biol. Chem*., **275**:22650-22656, 2000.
115. Sanchez-Prieto R., Rojas J.M., Taya Y., and Gutkind J.S. A role for the $p38^{MAPK}$ pathway in the transcriptional activation of p53 upon genotoxic stress by chemotherapeutic agents. *Cancer Res.,* **60:** 2464-2472, 2000.
116. Izevbige E.B.O., Gutkind J.S., and Ray P. E. Angiotensin II and Fibroblast Growth Factor mitogenic signaling pathways in human mesangial cells. *Pediatr. Res.,* **47:** 614-621, 2000.
117. Murga C., Fukuhara S., and Gutkind J.S. A novel role for PI3-kinase β in signaling from G protein-coupled receptors to Akt. *J. Biol. Chem.,* **275:** 12069-12073, 2000.
118. Chiariello M., Gomez E., and Gutkind J.S. Regulation of the mammalian G1/S cell cycle restriction point by MAP kinase. *J. Biochem.,* **349**:869-876, 2000.
119. Leethanakul C., Patel V., Gillespie J., Shillitoe E., Kellman R.M., Ensley J.E., Limwongse V., Emmert-Buck M.R., Krizman D.V., and Gutkind J.S. Gene expression profiles in squamous cell Carcinomas of the oral cavity: Use of Laser Capture Microdissection for the construction and analysis of stage-specific cDNA libraries. *Oral Oncology,* **36**:474-483, 2000.
120. Leethanakul C., Patel V., Gillespie J., Pallante M., Ensley J.F., Liotta L.A., Emmert-Buck M., and Gutkind J.S. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. *Oncogene,* **19**:3220-3224, 2000.
121. Izevbigie E.B.O., Gutkind J.S., and Ray P. Isoproterenol inhibits FGFb-induced growth of renal epithelial cells. *Ped. Nephrology,* **14:** 726-734, 2000.
122. Visconti R., Gadina M., Chiariello M., Chen E.H., Stancato L.F., Gutkind J.S., and O'Shea J.J. Importance of MKK6/p38 pathway for IL-12-induced STAT4 serine phosphorylation and transcriptional activity. *Blood,* **96:**1844-1852, 2000.
123. Arozarena I., Aaronson D.S., Sanz V., Ajenjo N., Matallanas D., Teramoto H., Iguishi T., Zabala J.S., Bustelo X.R., Gutkind J.S., and Crespo P. Ras-GRF-induced signaling and cellular transformation requires the participation of the GTPase cdc42. *J. Biol. Chem*., *J. Biol. Chem*., **275:** 26441-26448, 2000.
124. Hyun T., Yam A., Pece S., Xie X., Zhang J., Miki T., Gutkind J.S., and Li W. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. *Blood,* **96:**3560-3568, 2000.
125. Du Villard J.A., Wicker R., Crespo P., Russo D., Filetti S., Gutkind J.S., Sarasin A., and Suarez H.G. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation. *Oncogene,* **19:**4896-4905, 2000.
126. Fukuhara S. and Gutkind J.S. A new twist for the tumour suppressor hamartin. *Nature Cell Biol.,* **2:** E76-E78, 2000.

127. Fukuhara S., Marinissen M.J., Chiariello M., and Gutkind J.S. Signaling from G Protein-coupled receptors to ERK5/BMK 1 involves $G\alpha_q$ and $G\alpha_{12/13}$ families of heterotrimeric G proteins: Evidence for the existence of a novel Ras and Rho-independent pathway. *J. Biol. Chem.,* **275:** 21730-21736, 2000.
128. Sodhi A., Montaner S., Patel V., Zohar M., Bais C., Mesri E.A., and Gutkind J.S. The Kaposi's sarcoma associated Herpesvirus G protein-coupled receptor upregulates VEGF expression and secretion through MAPK and p38 pathways acting on HIF-1α. *Cancer Research*, **60:**4873-4880, 2000.
129. Patel V., Ensley J.F., Gutkind J.S., and Yeudall W.A. Induction of apoptosis in head and neck squamous carcinoma cells by γ-irradiation and bleomycin is p53-independent. *Internatl. J. Cancer*, **88:**737-743, 2000.
130. Fukuhara S., Chikumi H., and Gutkind J.S. Leukemia-Associated Rho Guanine Nucleotide Exchange Factor (LARG) links heterotrimeric G proteins of the G_{12} family to Rho. *FEBS Letters*, **485**:183-188, 2000.
131. Pece S. and Gutkind J.S. Signaling from E-Cadherins to the MAPK pathway by the recruitment and activation of EGF receptors upon cell-cell contact formation. *J Biol Chem*., **275**:41227-41233, 2000.
132. Marinissen M.J., Chiariello M., and Gutkind J.S. Regulation of gene expression by the small GTPase Rho through the ERK6 (p38γ) MAP kinase pathway. *Genes Dev*., **15**:535-553, 2001.
133. Patel V., Leethanakul C., and Gutkind J.S. New Approaches for the understanding of the molecular basis of oral cancer. *Crit. Rev. Oral Med.,* **12**:55-63, 2001.
134. Montaner S., Sodhi A., Pece S., Mesri E.A., and Gutkind J.S. The Kaposi's Sarcoma Associated Herpesvirus G Protein-Coupled Receptor promotes endothelial cell survival through the activation of Akt/PKB. *Cancer Res*., **61**:2641–2648, 2001.
135. Dong F., Gutkind J.S., and Larner A.C. Granulocyte colony-stimulating factor induces erk5 activation, which is differentially regulated by protein-tyrosine kinases and protein kinase C. Regulation of cell proliferation and survival. *J. Biol. Chem*., **276**:10811-10816, 2001
136. Yuan P.X., Huang L.D., Jiang Y.M., Gutkind J.S., Manji H.K., and Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. *J. Biol. Chem.,* **276**:31674-31683, 2001.
137. Longenecker K.L., Lewis M.E., Chikumi H., Gutkind J.S., and Derewenda Z.S. Structure of the RGS-like domain from PDZ-RhoGEF linking heterotrimeric G protein-coupled signaling to Rho GTPases. *Structure* (*Cell Press*), **9**:559-69, 2001.
138. Chiariello M., Marinissen M.J., and Gutkind J.S. Regulation of c-*myc* expression by PDGF through Rho GTPases. *Nature Cell. Biol.,* **3**:580-586, 2001.
139. Sodhi A., Montaner S., Miyazaki H., and Gutkind J.S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in ras V12 upregulation of VEGF. *Biochem. Biophys. Res. Commun*., **287**:292-300, 2001
140. Knezevic V., Leethanakul C., Bichsel B.E, Worth J.M., Prabhu V.V., Gutkind J.S., Liotta L.A., Munson P.J., Petricoin III E.F., and Krizman D.B. Proteomic profiling of the cancer microenvironment by antibody microarrays. *Proteomics*, **10**:1271-8, 2001.

141. Segrelles C., Ruiz S., Perez P., Murga C., Santos M., Budunova I.V., Martinez J., Larcher F., Slaga T.J., Gutkind J.S., Jorcano J.L., and Paramio J.M. Functional roles of Akt signaling in mouse skin tumorigenseis. *Oncogene*, **21**:53-64. 2002.
142. Murga C., Zohar M., Teramoto H., and Gutkind J.S. Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-κB. *Oncogene*, **21**:207-16, 2002.
143. Sakabe K., Teramoto H., Zohar M., Behbahani B., Miyazaki H., Chikumi H., and Gutkind J.S. Potent transforming activity of the small GTP-binding protein Rit in NIH 3T3 cells: Evidence for a role of a p38γ -dependent signaling pathway. *FEBS Lett.*, **511**:15-20, 2002
144. Katz B.Z., Miyamoto S., Teramoto H., Zohar M., Krylov D., Vinson C., Gutkind J.S., and Yamada K.M. Direct transmembrane clustering and cytoplasmic dimerization of focal adhesion kinase initiates its tyrosine phosphorylation. *Biochim. Biophys. Acta*, **1592**: 141-152, 2002.
145. Chen H.W., Chen X., Oh S.W., Marinissen M.J., Gutkind J.S., and Hou S.X. Mom identifies a receptor for the Drosophila JAK/STAT signal transduction pathway and encodes a protein distantly related to the mammalian cytokine receptor family. *Genes Dev*., **16**:388-398, 2002.
146. Orsulic S., Li Y., Soslow R.A., Vitale-Cross L.A., Gutkind J.S., and Varmus H.E. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. *Cancer Cell*, **1**: 53-62, 2002.
147. Chikumi H., Fukuhara S., and Gutkind J.S. Regulation of G protein-linked guanine nucleotide exchange for Rho, PDZ-RhoGEF and LARG, by tyrosine phosphorylation: Evidence of a role for FAK. *J. Biol. Chem.*, **277**:12463-12473, 2002.
148. Chen H.W., Marinissen M.J., Oh S.W., Chen X., Melnick M., Perrimon N., Gutkind J.S., and Hou S.X. CKA, a novel multidomain protein, regulates the JUN N-terminal kinase signal transduction pathway in Drosophila. *Mol. Cell. Biol.*, **22**:1792-803, 2002.
149. Sanchez-Prieto R., Sanchez-Arevalo V.J., Servitja J.-M., and Gutkind J.S. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. *Oncogene*, **31**:974-979, 2002.
150. Regnauld K.L., Leteurtre E., Gutkind J.S., Gespach C.P., and Emami S. Activation of adenylyl cyclases, regulation of insulin status, and cell survival by G(alpha)olf in pancreatic beta-cells. *Am. J. Physiol.*, **282**:R870-880, 2002.
151. Patel V., Lahusen T., Sy T., Sausville E.A., Gutkind J.S., and Senderowicz A.M. Perifosine, a novel alkylphospholipid, induces $p21^{(WAF1)}$ expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. *Cancer Res.*, **62**:1401-1409, 2002.
152. Patel V., Aldridge K., Ensley J.F., Odell E., Boyd A., Jones J., Gutkind J.S., and Yeudall W.A. Laminin-gamma2 overexpression in head-and-neck squamous cell carcinoma. *Internatl. J. Cancer*, **99**:583-588, 2002.
153. Machado de Sousa S.O., Mesquita R.A, Pinto Jr D.S., and Gutkind J.S. Immunolocalization of c-Fos and c-Jun in human oral mucosa and in oral squamous cell carcinoma. *J. Oral Pathol.*, **31**:78-81, 2002.
154. Choi Y., Zhang J., Murga C., Yu H., Koller E., Monia B.P., Gutkind J.S., and Li W. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. *Oncogene*, **21**:5289-5300, 2002.

155. Chikumi H., Vazquez-Prado J., Servitja J.-M., Miyazaki H., and Gutkind J.S. Potent activation of RhoA by Gαq and Gq-coupled receptors. *J. Biol. Chem.,* **277**:27130-27134, 2002.
156. Perrot V., Vázquez-Prado J., and Gutkind J.S. Plexin B Regulates Rho through the Guanine Nucleotide Exchange Factors LARG and PDZ-RhoGEF. *J. Biol. Chem.*, **277**:43115-43120, 2002.
157. Patel V., Lahusen T., Leethanakul C., Igishi T., Kremer M., Quintanilla-Martinez L., Ensley J.F., Sausville E.A., Gutkind J.S., and Senderowicz A.M. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27KIP1. *Clin. Cancer Res*. **8**:3549-3560, 2002.
158. Aurandt J., Vikis H.G., Gutkind J.S., Ahn N., and Guan K.-L. The semaphorin receptor plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. *Proc. Natl. Acad. Sci.,* **99**:12085-12090, 2002.
159. Guo Y.S., Cheng J.Z., Jin G.F., Gutkind J.S., Hellmich M.R., and Townsend C.M. Jr. Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of EGF receptor. *J. Biol. Chem.*, **277**:48755-48763, 2002.
160. Leethanakul C., Knezevic V., Patel V., Amornphimoltham P., Gillespie J., Shillitoe E.J., Emkoe P., Park M.H., Emmert-Buck M.R., Strausberg R.L., Krizman D.B., and Gutkind J.S. Gene Discovery in Oral Squamous Cell Carcinoma through the Head and Neck Cancer Genome Anatomy Project: Confirmation by Microarray Analysis. *Oral Oncol.,* **39**:248-258, 2003.
161. Montaner S., Sodhi A., Molinolo A., Bugge T.H., Sawai E.T., He Y., Li Y., Ray P.E., and Gutkind J.S. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. *Cancer Cell*, **3**:23-36, 2003.
162. Servitja J.-M., Masgrau R., Pardo R., Sarri E., von Eichel-Streiber C., Gutkind J.S., and Picatoste F. Metabotropic glutamate receptors activate phospholipase D in astrocytes through a protein kinase C-dependent and Rho-independent pathway. *Neuropharmacol*., **44**:171-80, 2003.
163. Nishigaki K., Thompson D., Yugawa T., Rulli K., Hanson C., Cmarik J., Gutkind J.S., Teramoto H., and Ruscetti S. Identification and characterization of a novel Ste-20/GCK-related kinase, PAP kinase (PAPK). *J. Biol Chem*., **278**:13520-13530, 2003.
164. Sriuranpong V., Park J.I., Amornphimoltham P., Patel P., Nelkin B.D., and Gutkind J.S. EGFR-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the IL6/gp130 cytokine system. *Cancer Research*, **63**:2948-2956, 2003.
165. Teramoto H., Malek R.L., Behbahani B., Castellone M.D., Lee N.L., and Gutkind J.S. Identification of H-Ras, RhoA, Rac1 and Cdc42 responsive genes. *Oncogene,* **22**:2689-2697, 2003.
166. Pedersen T.X., Leethanakul C., Patel V., Mitola D., Lund L.R., Dano K., Johnsen M., Gutkind J.S., and Bugge T.H. Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma. *Oncogene,* **22**:3964-3976, 2003.

167. Servitja J.M., Marinissen M.J., Sodhi A., Bustelo X.R., and Gutkind J.S. Rac1 function is required for Src-induced transformation: Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. *J. Biol. Chem.*, **278**:34339-34346, 2003.
168. Monje P., Marinissen M.J., and Gutkind J.S. The phosphorylation of the carboxyl-terminal transactivation domain of c-Fos by ERK mediates the transcriptional activation of AP-1 and cellular transformation induced by PDGF. *Mol. Cell. Biol.,* **23**:7030-7043, 2003.
169. Marinissen M.J., Servitja J.-M., Offermanns S., Simon M.I., and Gutkind J.S. The thrombin receptor PAR-1 signals through G_q and G_{13}-initiated MAPK cascades regulating c-Jun expression to induce cell transformation. *J. Biol. Chem.*, **278**:46814-46825, 2003.
170. Iavarone C., Catania A., Marinissen M.J., Visconti R., Acunzo M., Tarantino C., Carlomagno M.S., Bruni C.B., Gutkind J.S., and Chiariello M. PDGF controls c-*myc* expression through a JNK- and AP-1-dependent signaling pathway. *J. Biol. Chem.*, **278**: 50024-50030, 2003.
171. Chikumi H., Barac A., Behbahani B., Gao Y., Teramoto H., Zheng Y., and Gutkind J.S. Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their *in vivo* Rho GEF activity and transforming potential. *Oncogene,* **23**:233-240, 2004.
172. Barac A., Basile J., Vazquez-Prado J., Gao Y., Zheng Y., and Gutkind J.S. Direct interaction of PAK4 with PDZ-RhoGEF, a G protein-linked Rho guanine exchange factor. *J. Biol. Chem.*, **279**:6182-6189, 2004.
173. Sodhi A., Montaner S., and Gutkind J.S., Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's Sarcomagenesis? *Faseb J.*, **18**:422-427, 2004.
174. Sodhi A., Montaner S., Patel V., Román J.G., Li Y., Sausville E.A., Sawai E.T., and Gutkind J.S. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. *Proc. Natl. Acad. Sci. U.S.A.,* **101**:4821-4826, 2004.
175. Amornphimoltham P., Sriuranpong V., Patel V., Benavides F., Conti C.J., Sauk J., Sausville E.A., Molinolo A.A., and Gutkind J.S., Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01, *Clin. Cancer Research,* **10**:4029-4037, 2004.
176. Sriuranpong V., Mutirangura A., Gillespie J.W., Patel V., Amornphimoltham P., Molinolo A.A., Kerekhanjanarong V., Supanakorn S., Supiyaphun P., Rangdaeng S., Voravud N., and Gutkind J.S. Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and cDNA microarrays. *Clin. Cancer Research,* **10**:4944-4958, 2004.
177. Basile J.R., Barac A., Zhu T., Guan K.-L., and Gutkind J.S. Class IV Semaphorins promote angiogenesis by stimulating Rho-initiated pathways through Plexin-B, *Cancer Research,* **64**:5212-5224, 2004.
178. Oliva J.L., Zarich N., Martínez J.R., Castrillo A., Azañedo M., García-Vargas S., Juarranz A., Boscá L., Gutkind J.S., and Rojas J.M. The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH3T3 cells but not of H-Ras. *J. Biol. Chem,* **279**:33480-33491, 2004.
179. Rosenfeldt H., Vazquez-Prado J., and Gutkind J.S. P-Rex2, a novel PI-3-Kinase sensitive Rac exchange factor. *FEBS Lett.,* **572**:167-71, 2004.

180. Jeon G.A., Lee J.-S., Patel V., Gutkind J.S., Thorgeirsson S.S., Kim E.C., Amornphimoltham P., and Park M.H. Global gene expression profiles of human head and neck squamous carcinoma cells, *Internatl. J. Cancer*, **112**:249-258, 2004.
181. Kesavapany S., Amin N., Zheng Y.-L., Nijhara R., Jaffe H., Sihag R., Gutkind J.S., Takahashi S., Kulkarni A., Grant P., and Pant H.C. p35/Cdk5 phosphorylation of RasGRF2 mediates Rac-depependent ERK1/2 activity, altering RasGRF2 and MAP1b distribution in neurons. *J. Neurosc*., **24**:4421-4433, 2004.
182. Curino A., Patel V., Schnack-Nielsen B., Iskander A.J., Ensley J.F., Yoo G., Holsinger C., Myers J.N., Shillitoe E.J., Molinolo A.A., Gutkind J.S., and Bugge T.H. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. *Oral Oncol.*, **40**:1026-1032, 2004.
183. Montaner S., Sodhi A., Servitja J.-M., Ramsdell A.K., Barac A., Sawai E.T., and Gutkind J.S. The small GTPase Rac1 links the Kaposi's Sarcoma Herpesvirus vGPCR to NFκB-mediated transcription and secretion of IL-6 and paracrine neoplasia. *Blood*, **104**:2903-2911, 2004.
184. Vitale-Cross L., Amornphimoltham P., Fisher G., Molinolo A.A., and Gutkind J.S. Conditional expression of K-ras in an epithelial compartment that includes the stem-cells is sufficient to promote squamous cell carcinogenesis. *Cancer Res.*, **64**:8804-8807, 2004.
185. Marinissen M.J., Chiariello M., Tanos T., Bernard O., Narumiya S., and Gutkind J.S. The small GTP-binding protein RhoA regulates c-Jun by a ROCK-JNK signaling axis, *Mol. Cell*, **14**:29-41, 2004.
186. Vazquez-Prado J., Miyazaki H., Castellone M.D., Teramoto H., and Gutkind J.S. Chimeric $G\alpha_{i2}/G\alpha_{13}$ proteins reveal the structural requirements for the binding and activation of RGL-containing Rho GEFs by $G\alpha_{13}$. *J. Biol. Chem.*, **279**:54283-54290, 2004.
187. Baker H., Patel V., Molinolo A.A., Myers J.N., El-Naggar A.K., Gutkind J.S., and Hancock W.S. Proteome-wide analysis of head and neck squamous cell carcinomas using laser-capture microdissection and tandem mass-spectrometry, *Oral Oncol.*, **41**:183-199, 2005.
188. Teramoto H., Castellone M.D., Malek R.L., Behbahani B., Letwin N., Gutkind J.S, and Lee N.H. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12, *Oncogene*, **24**:489-501, 2005.
189. Brantley E., Patel V., Stinson S.F., Trapani V., Hose C.D., Ciolino H.P., Yeh G.C., Gutkind J.S., Sausville E.A., and Loaiza-Perez A.I. The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells. *Anticancer Drugs*, **16**:137-143, 2005.
190. Patel V., Ramesh A., Traicoff J.L., Baibakov G., Emmert-Buck M.R., Gutkind J.S., and Knezevic V. Profiling EGFR activity in head and neck squamous cell carcinoma by using a novel layered membrane Western blot technology. *Oral Oncol*., **41**:503-508, 2005.
191. Tanos T., Marinissen M.J., Coluccio Leskow F., Hochbaum D., Martinetto H., Gutkind J.S., and Coso O.A. Phosphorylation of c-Fos by members of the p38 MAPK family: Role in the AP-1 response to UV. *J. Biol. Chem.*, **280**:18842-18852, 2005.
192. Yeudall W.A., Miyazaki H., Ensley J.F, Cardinali M., Gutkind J.S., Patel V. Uncoupling of Epidermal Growth Factor-dependent proliferation and invasion in a model of squamous carcinoma progression. *Oral Oncol.*, **41**:698-708, 2005.

193. List K., Szabo R., Molinolo A., Sriuranpong V., Redeye V., Burke B., Murdock T., Nielsen B.S., Gutkind J.S., and Bugge T. H. Deregulated matriptase proteolysis causes *ras*-independent multistage carcinogenesis and promotes *ras*-mediated malignant transformation. *Genes Dev.*, **19:**1934-1950, 2005.
194. Basile J.R., Afkhami T., and Gutkind J.S. Semaphorin 4D/Plexin-B1 Induces Endothelial Cell Migration through the Activation of PYK2, Src and the PI3K-Akt pathway. *Mol. Cell. Biol*, **25**:6889-6898, 2005.
195. Monje P., Hernández-Losa J., Castellone M.D., Lyons R., and Gutkind J.S. Regulation of the transcriptional activity of c-Fos by ERK: A novel role for the prolyl-isomerase Pin1. *J. Biol. Chem.*, **280**:35081-35084, 2005.
196. Amornphimoltham P., Patel V., Sodhi A., Nikitakis N.G., Sauk J.J., Sausville E.A., Molinolo A.A., and Gutkind J.S. mTOR, a molecular target in squamous cell carcinomas of the head and neck. *Cancer Research*, **65**:9953-9961, 2005.
197. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., and Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a novel Gs-axin-β-catenin signaling axis. *Science*, **310**:1504-1510, 2005.
198. Montaner S., Sodhi A., Ramsdell A.K., Martin D., Hu J., Sawai E.T., and Gutkind J.S., The Kaposi's sarcoma associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. *Cancer Research.*, **66**:168-174, 2006.
199. Miyazaki H., Patel V., Wang H., Ensley J.F., Gutkind J.S., Yeudall W.A. Growth factor-sensitive molecular targets identified in primary and metastatic head and neck squamous cell carcinoma using microarray analysis. *Oral Oncol.*, **42**:240-256, 2006.
200. Kaur S., Castellone M.D., Bedell V.M., Konar M., Gutkind J.S., and Ramchandran R. Robo4 signaling in endothelial cells implies attraction guidance mechanisms. *J. Biol. Chem.*, **281:** 1347-1356, 2006.
201. Raimondi R.R., Vitale-Cross L., Amornphimoltham P., Gutkind J.S., and Molinolo A.A. Rapid development of salivary gland carcinomas upon conditional expression of K-ras driven by the cytokeratin 5 promoter. *Amer. J. Pathol.*, **168**:1654-1565, 2006.
202. Kehat I., Heinridh R., Ofer B-I., Miyazaki H., Gutkind J.S., and Aronheim A. Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation. *Cardiovasc Res.* **70**:543-554, 2006.
203. Gu J., Wu X., Dong Q., Romeo M.J., Lin X., Gutkind J.S., and Berman D.M. A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans. *Cancer*, **106**:2716-2724, 2006.
204. Basile J.R., Castilho R.M., Williams V.P., and Gutkind JS. Semaphorin4D provides a link between anon guidance processes and tumor-induced angiogenesis, *Proc. Natl. Acad. Sci. U.S.A.*, **103**:9017-9022, 2006.
205. Gelbard A., Garnett C.T., Abrams S.I., Patel V., Gutkind J.S., Palena C., Tsang K.-Y., Schlom J., and Hodge J.W. Combination chemotherapy and radiation of human squamous cell Carcinoma of the head and neck augments CTL-mediated lysis. *Clin. Cancer Research*, **12**:1897-1905, 2006.
206. Gavard J. and Gutkind J.S. VEGF controls endothelial cell permeability by promoting the β-arrestin-dependent endocytosis of VE-cadherin. *Nature Cell. Biol.*, **11**:1223-1234, 2006.

207. Sodhi A., Chaisuparat R., Hu J., Ramsdell A.K., Manning B.D., Sausville E.A., Sawai E.T., Molinolo A., Gutkind J.S., and Montaner S. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's Sarcoma Associated Herpesvirus G Protein-Coupled Receptor. *Cancer Cell*, **10**:133-143, 2006.
208. Squarize C.H., Castilho R.M., Sriuranpong V., Pinto Jr. D.C., and Gutkind J.S. A molecular cross-talk between the NFκB and STAT3 signaling pathways in head and neck squamous cell carcinoma. *Neoplasia*, **8**:733-746, 2006.
209. Rosenfeldt H., Castellone M.D. Randazzo P.A., and Gutkind J.S. Rac inhibits thrombin-induced Rho activation: Evidence of a Pak-dependent GTPase crosstalk. *J. Cell Signal.*, **1**:8, 2006.
210. Tan W., Martin D., and Gutkind J.S. The $G\alpha_{13}$-Rho signaling axis is required for SDF-1 induced migration through CXCR4. *J. Biol. Chem.*, **281**:39542-39549, 2006.
211. Yu X., Munge B., Patel V., Jensen G., Bhirde A., Gong J.D., Kim S., Gillespie J., Gutkind J.S., Papadimitrakopoulos F., and Rusling J.F. Carbon nanotube amplification strategies for highly sensitive immunosensing of cancer biomarkers in serum and tissue. *J. Amer. Chem. Soc.*, **128**:11199-11205, 2006.
212. Teramoto H., Miwa H., Patel V., Letwin N., Castellone M.D., Imai N., Shikami M., Imamura A., Gutkind J.S., Nitta M., Lee N.H. Gene expression changes in a patient presenting nonleukaemic nasal granulocytic sarcoma to acute myelogenous leukaemia using 40 K cDNA microarray. *Clin. Lab. Haematol.*, **28**:262-266, 2006.
213. Sanchez V.M., Crespo A., Gutkind J.S., and Turjanski A.G. Investigation of the catalytic mechanism of farnesyl pyrophosphate synthase by computer simulation. *J. Phys. Chem.*, **110**:18052-18057, 2006.
214. Kesavapany S., Pareek T.K., Zheng Y.L., Amin N., Gutkind J.S., Ma W., Kulkarni A.B., Grant P., and Pant H.C. Neuronal nuclear organization is controlled by cyclin-dependent kinase 5 phosphorylation of Ras guanine nucleotide releasing factor-1. *Neurosignals*, **15**:157-173, 2006.
215. Miyazaki H., Patel V., Wang H., Edmunds R.K., Gutkind J.S., and Yeudall W.A. Down-regulation of CXCL5 inhibits squamous carcinogenesis. *Cancer Research*, **66**: 4279-4284, 2006.
216. Touge H., Chikumi H., Igishi T., Kurai J., Makino H., Tamura Y., Takata M., Yoneda K., Nakamoto M., Suyama H., Gutkind J.S., and Shimizu E. Diverse activation states of RhoA in human lung cancer cells: Contribution of G protein coupled receptors. *Int. J. Oncol.*, **30**:709-715, 2007.
217. Basile J.R., Holmbeck K., Bugge T.H., and Gutkind J.S. MT1-MMP controls tumor-induced angiogenesis through the release of Semaphorin 4D. *J. Biol. Chem.*, **282**:6899-6905, 2007.
218. Castilho R.M., Squarize C.H., Patel V., Millar S.E., Zheng Y., Molinolo A., and Gutkind JS. Requirement of Rac1 distinguishes follicular from interfollicular epithelial stem cells. *Oncogene*, **26**:5078-5085, 2007.
219. Turjanski A.G., Vaqué J.P., and Gutkind J.S. MAP Kinases and the Control of Nuclear Events. *Oncogene*, **26**:3240-3253, 2007.
220. Montero-Girard G., Vanzulli S.I., Cerliani J.P., Bottino M.C., Bolado J., Vela J., Becu-Villalobos D., Benavides F., Gutkind J.S., Patel V., Molinolo A., and Lanari C. Association of estrogen receptor-alpha and progesterone receptor A expression with

hormonal mammary carcinogenesis: role of the host microenvironment. *Breast Cancer Res.*, **9**:R22, 2007.

221. Kupferman M.E., Patel V., Sriuranpong V., Amornphimoltham P., Jasser S.A., Mandal M., Zhou G., Wang J., Coombes K., Multani A., Pathak S., Gutkind J.S., and Myers J.N. Molecular analysis of anoikis resistance in oral cavity squamous cell carcinoma. *Oral Oncol*., **43**:440-454, 2007.
222. Patel V., Rosenfeldt H., Lyons R., Servitja J.-M., Bustelo X.R., Siroff M., and Gutkind J.S. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR-Vav2 signaling axis involved in cell invasion. *Carcinogenesis* **28**:1145-1152, 2007.
223. Hernandez-Negrete I., Carretero-Ortega J., Rosenfeldt H., Hernandez-Garcia R., Calderon-Salinas J.V., Reyes-Cruz G., Gutkind J.S., and Vazquez-Prado J. P-Rex1 links mTOR signaling to Rac activation and cell migration. *J. Biol. Chem.*, **282**:23708-23715, 2007.
224. Honjo Y., Bian Y., Kawakami K., Molinolo A., Longenecker G., Boppana R., Larsson J., Karlsson S., Gutkind J.S., Puri R.K., and Kulkarni A.B. TGF-beta receptor I conditional knockout mice develop spontaneous squamous cell carcinoma. *Cell Cycle*, **6**:1360-1366, 2007.
225. Liu H., Fergusson M.M., Castilho R.M., Liu J., Liu C., Chen J., Malide D., Rovira I.I., Schimel D., Kuo K.J., Gutkind J.S., Hwang P.M., and Finkel T. Augmented Wnt signaling in a mammalian model of accelerated aging. *Science*, **317**:803-806, 2007.
226. Molinolo A.A., Hewitt S., Amornphimoltham P., Keelawat S., Rangdaeng S., Meneses García A., Raimondi A.R., Jufe R., Itoiz M., Gao Y., Saranath D., Kaleebi G.S., Yoo G.H., Leak L., Myers E.M., Shintani S., Wong D., Massey H.D., Yeudall W.A., Lonardo F., Ensley J., and Gutkind J.S. Dissecting the Akt/mTOR signaling network: Emerging results from the Head and Neck Cancer Tissue Array Initiative. *Clin. Cancer Research*, **13**:4964-4973, 2007.
227. Wagenaar-Miller R.A., Engelholm L.H., Gavard J., Yamada S.S., Gutkind J.S., Behrendt N., Bugge T.H., and Holmbeck K. Complementary roles of intracellular and pericellular collagen degradation pathways *in vivo*. *Mol. Cell. Biol.*, **27:**6309-6322, 2007.
228. Kesavapany S., Patel V., Zheng Y.L., Pareek T.K., Bjelogrlic M., Albers W., Amin N., Jaffe H., Gutkind J.S., Strong M.J., Grant P., and Pant H.C. Inhibition of Pin1 Reduces Glutamate-induced perikaryal accumulation of phosphorylated neurofilament-H in neurons. *Mol. Biol. Cell.*, **18**:3645-3655, 2007.
229. Martin M.J., Tanos T.B., Garcia A.B., Martin D., Gutkind J.S., Coso O.A., Marinissen M.J. The Galpha 12/13 family of heterotrimeric G proteins and the small GTPase RhoA link the Kaposi sarcoma-associated herpes virus-G protein coupled receptor to heme oxygenase-1 expression and tumorigenesis. *J. Biol. Chem.*, **282**:34510-34524, 2007.
230. Basile J.R., Gavard J., Gutkind J.S. Plexin-B1 utilizes RHOA and ROK to promote the integrin-dependent activation of AKT and ERK, and endothelial cell motility. *J. Biol. Chem.*, **282**:34888-34895, 2007.
231. Wirth A., Benyó Z., Lukasova M., Leutgeb B., Wettschureck N., Gorbey S., Örsy P., Horváth B., Maser-Gluth C., Greiner E., Lemmer B., Schütz G., Gutkind S., and Offermanns S. G12-G13–LARG–mediated signaling in vascular smooth muscle is required for salt-induced hypertension. *Nature Medicine*, **14**:64-68, 2008.

232. Liu S., Wang H., Currie B.M., Molinolo A., Leung H.J., Moayeri M., Basile J.R., Alfano R.W., Gutkind J.S., Frankel A.E., Bugge T.H., and Leppla S.H.. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. *J. Biol. Chem.*, **283**:529-540, 2008.
233. Gavard J., Patel V., and Gutkind J.S. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. *Dev. Cell*, **14**:25-36, 2008.
234. Wolf J., Palmby T.R., Gavard J., Williams B.O, and Gutkind J.S. Multiple PPPS/TP motifs act in a combinatorial fashion to transduce Wnt Signaling through LRP6. *FEBS Lett.*, **582**:255-261, 2008.
235. Martin D., Galisteo R., Ji Y., Montaner S., and Gutkind J.S. A NF-κB gene expression signature contributes to Kaposi's Sarcoma Virus vGPCR-induced direct and paracrine neoplasia. *Oncogene*, **27**:1844-1852, 2008.
236. Galan-Moya E.M., Hernandez-Losa J., Aceves Luquero C.I., de la Cruz-Morcillo M.A., Ramírez-Castillejo C., Callejas-Valera J.L., Arriaga A., Fernandez Aranburo A, Ramón y Cajal S., Gutkind J.S., and Sánchez-Prieto R. c-Abl activates p38 MAPK independently of its tyrosine kinase activity: implications in cisplatin based therapy. *Int. J. Cancer*, **122**: 289-297, 2008.
237. Amornphimoltham P., Patel V., Leelahavanichkul K., Abraham R.T, and Gutkind J.S. A retro-inhibition approach reveals a tumor cell-autonomous therapeutic response to rapamycin in head and neck squamous cell carcinomas. *Cancer Research*, **68**:1144-1153, 2008.
238. Patel V., Hood B.L., Molinolo A.A., Lee N.H, Conrads T.P., Braisted J.C., Krizman D.B., Veenstra T.D., Gutkind J.S. Proteomic analysis of laser-captured paraffin embedded tissues: A molecular portrait of head and neck cancer progression. *Clin. Cancer Research*, **14**:1002-1014, 2008.
239. Gómez-Román J.J., Garay G.O., Saenz P., Escuredo K., Ibayondo C.S., Junquera C., Gutkind J.S., Belaustegui-Trías C., Simón L., Martínez A., Fernández-Luna J.L., Val-Bernal J.F. Plexin B1 is downregulated in renal neoplasmas and modulates cell growth. *Trans. Res.*, **151**:134-140, 2008.
240. Zhou G., Xie T-X., Zhao M., Jasser S.A., Younes M.N., Sano D., Lin J., Kupferman M.E., Santillan A.A., Patel V., Gutkind J.S., EI-Naggar A.K., Emberley E.D., Watson P.H., Matsuzawa S-I., Reed J.C., and Myers J.N. Reciprocal negative regulation between S100A7/psoriasin and bold beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. *Oncogene*, **25**:3527-3538, 2008.
241. Sausville J., Molinolo A.A., Cheng X., Frampton J., Takebe N., Gutkind J.S., and Feldman R.A. RCAS/SCL-TVA animal model allows targeted delivery of PyMT oncogene to vascular endothelial progenitors in vivo, and results in rapid hemangioma. *Clin. Cancer Research*, **14**:3948-3955, 2008.
242. Turjanski A.G., Gutkind J.S., Best R.B., and Hummer G. Binding-induced folding of a natively unstructured transcription factor. *PLoS Computational Biology*, 4:e1000060.
243. Lyons J.G., Patel V., Roue1 N., Fok S.Y., Soon L.L., Halliday J.M., and Gutkind J.S. Snail expression in oral keratinocytes up-regulates pro-inflammatory mediators and inhibits terminal differentiation. *Cancer Research*, **68**:4525-4530, 2008
244. Sun C., Dobi A., Mohamed A., Li H., Thangapazham R.L., Furusato B., Shaheduzzaman S., Tan S.H., Vaidyanathan G., Whitman E., Hawksworth D.J., Chen Y., Nau M., Patel V., Vahey M., Gutkind J.S., Sreenath T., Petrovics G., Sesterhenn I.A., McLeod D.G.,

Srivastava S.TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. *Oncogene* **27**:5348-5353, 2008.

245. Yamaza T., Miura Y., Bi Y., Liu Y., Akiyama K., Sonoyama W., Patel V., Gutkind J.S., Young M., Gronthos S., Le A., Wang C.Y., Chen W., and Shi S. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. *PLoS ONE*. 2008 Jul 9;3(7):e2615.
246. Squarize C.H., Castilho R.M., and Gutkind J.S. Chemoprevention of experimental Cowden's Disease by mTOR inhibition with rapamycin. *Cancer Research*, **68**:7066-7072.
247. Paccione R.J., Miyazaki H., Patel V., Waseem A., Gutkind J.S., Zehner Z.E., and Yeudall W.A. Keratin down-regulation in vimentin-positive cancer cells is reversible by vimentin RNA interference, which inhibits growth and motility. *Mol. Cancer. Ther*. **7**:2894-2903, 2008.
248. Gavard J. and Gutkind J.S. Protein Kinase C-related Kinase and ROCK are required for thrombin-induced endothelial cell permeability downstream from $G\alpha_{12/13}$ and $G\alpha_{11/q}$. *J. Biol. Chem.*, **283**:29888-29896, 2008.
249. Schneider A., Younis R.H., and Gutkind J.S. Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. *Neoplasia* **10**:1295-1302, 2008.
250. Tan W., Palmby T.R., Gavard J., Amornphimoltham P., Zheng Y, and Gutkind J.S. An essential role for Rac1 in endothelial cell function and vascular development. *FASEB J*., **22**:1829-1838, 2008.
251. Amornphimoltham A., Leelahavanichkul K., Molinolo A.A., Patel V., and Gutkind J.S. Inhibition of mTOR by rapamycin causes the regression of carcinogen-induced skin tumor lesions. *Clin. Cancer Research*, **14**:8094-8101, 2008.
252. Czerninski R., Amornphimoltham P., Patel V., Molinolo A.A., and Gutkind J.S. Targeting mTOR by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. *Cancer Prevention Research*, **2**:27-36, 2009.
253. Wang H., Patel V., Miyazaki H., Gutkind J.S., and Yeudall W.A. Role for EPS8 in squamous carcinogenesis. *Carcinogenesis*, **30**:165-174, 2009.
254. Bhirde A.A.,, Patel V., Gavard J., Zhang G., Sousa A.A., Masedunskas A., Leapman R.D., Weigert R., Gutkind J.S., and Rusling J.F. Targeted killing of cancer cells *in vivo* and *in vitro* with EGF-directed carbon nanotube-based drug delivery. *Am. Chem. Soc. Nano*, **3**:307-316, 2009.
255. Castellone M.D., De Falco V., Rao D.M., Bellelli R., Muthu M., Basolo F., Fusco A., Gutkind J.S., and Santoro M. The β-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. *Cancer Res*. **69**:1867-1876, 2009.
256. Munge B.S., Krause C.E., Malhotra R., Patel V., Gutkind J.S., and Rusling J.F. Electrochemical immunosensors for interleukin-6. Comparison of carbon nanotube forest and gold nanoparticle platforms. Electrochem. Commun. **11**:1009-1012, 2009.
257. Mani V., Chikkaveeraiah B.V., Patel V., Gutkind J.S., Rusling J.F. Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification. *Am. Chem. Soc. Nano*, **3**:585-594, 2009.

258. Gavard J., Hou X., Qu Y., Masedunskas A., Martin D., Weigert R., Li X., and Gutkind J.S. A Role for a CXCR2/PI3Kγ signaling axis in acute and chronic vascular permeability. *Mol. Cell Biol*., **29**:2469-2480, 2009.
259. Sako K., Fukuhara S., Minami T., Hamakubo T., Song H., Kodama T., Fukamizu A., Gutkind J.S., Koh G.Y., and Mochizuki N. Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2. *J. Biol. Chem*, **284**:5592-5601, 2009.
260. Cheong S.C., Chandramouli G.V., Saleh A., Zain R.B., Lau S.H., Sivakumaren S., Pathmanathan R., Prime S.S., Teo S.H., Patel V., and Gutkind J.S. Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure. *Oral Oncol*., **45**:712-719, 2009.
261. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates VEGF expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFκB through the CBM (Carma3/Bcl10/Malt1) complex. *J. Biol. Chem.*, **284**:6038-6042, 2009.
262. Turjanski A.G., Hummer G., and Gutkind J.S. How mitogen-activated protein kinases recognize and phosphorylate their targets: A QM/MM study. *J. Amer. Chem. Soc*., **131**:6141-6148, 2009.
263. Raimondi A.R., Molinolo A., and Gutkind J.S. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-*ras* and *p53* two-hit carcinogenesis model. *Cancer Research*, **69**:4159-4166, 2009.
264. Guzmán-Hernández M.L., Vázquez-Macías A., Carretero-Ortega J., Hernández-García R., García-Regalado A., Hernández-Negrete I., Reyes-Cruz G., Gutkind J.S., Vázquez-Prado J. Differential inhibitor of Gβγ-signaling to AKT and ERK derived from Phosducin-like protein: Effect on sphingosine-1-phosphate-induced endothelial cell migration and *in vitro* angiogenesis. *J. Biol. Chem*., **284**:18334-188346, 2009.
265. Bian Y., Terse A., Du J., Hall B., Molinolo A., Zhang P., Chen W., Flanders K.C., Gutkind J.S., Wakefield L.M., and Kulkarni A.B. Progressive tumor formation in mice with conditional deletion of TGF-β signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. *Cancer Research*, **69**:5918-5926, 2009.
266. Bhirde A.A., Sousa A.A., Patel V., Azari A.A., Gutkind J.S., Leapman R.D. and Rusling J.F. Single-molecule imaging and quantitation of a platinum-based drug attached to single-wall carbon nanotubes. *Nanomedicine* **4**:763-772, 2009.
267. Chikkaveeraiah B.V., Bhirde A., Malhotra R., Patel V., Gutkind J.S., Rusling J.F. Single-wall carbon nanotube forest arrays for immunoelectrochemical measurement of four protein biomarkers for prostate cancer. *Anal Chem* **81**:9129-9134, 2009.
268. Castilho R.M., Squarize C.H., Chodosh L.A., Williams B.O., and Gutkind J.S. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. *Cell Stem Cell*, **5**:279-289, 2009.
269. Gonzalez-Pardo V., Martin D., Gutkind J.S., Verstuyf A., Bouillon R., de Boland A.R., and Boland R.L. 1alpha,25-dihydroxyvitamin D3 and its TX527 analog inhibit the growth of endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein-coupled receptor in vitro and in vivo. *Endocrinology*, 151:23-31, 2010.
270. Malhotra R., Patel V., Vaqué J.P., Gutkind J.S., and Rusling J.F. Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification. *Anal Chem*. **82**:3118-3123, 2010.

271. Sakurai A., Gavard J., Annas-Linhares Y., Basile J.R., Amornphimoltham P., Palmby T.R., Yagi H., Zhang F., Randazzo P.A., Li X., Weigert R., and Gutkind J.S. Semaphorin 3E initiates anti-angiogenic signaling through Plexin-D1 by regulating Arf6 and R-Ras. *Mol. Cell Biol*,. 2010 Apr 12. [Epub ahead of print].
272. Wang H., Teh M.T., Ji Y., Patel V., Firouzabadian S., Patel A.A,. Gutkind J.S., and Yeudall W.A. EPS8 upregulates FOXM1 expression, enhancing cell growth and motility. Carcinogenesis. 2010 Mar 29. [Epub ahead of print].
273. Castilho R.M., Squarize C.H., Leelahavanichkul K., Zheng Y., Bugge T., and Gutkind J.S. Rac1 is required for epithelial stem cell function during dermal and oral mucosal wound healing but not for tissue homeostasis in mice. *PloS ONE*, **5**: e10503, 2010.
274. Squarize C.H., Castilho R.M., Bugge T., and Gutkind J.S. Accelerated wound healing by mTOR activation in genetically defined mouse models. *PloS ONE*, **5**: e10643, 2010.
275. Weller M.L., Amornphimoltham P., Schmidt M., Wilson P.A., Gutkind J.S., and Chiorini J.A. Epidermal growth factor receptor is a receptor for adeno-associated virus serotype 6. *Nature Medicine*, **16:**662-664, 2010.
276. Abrahao A.C., Castilho R.M,. Squarize C.H., Molinolo A.A., Santos-Pinto D.D. Jr, and Gutkind J.S. A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. *Oral Oncol*., **46:**880-887, 2010.
277. Giulianelli S., Herschkowitz J.I., Patel V., Lamb C.A., Gutkind J.S., Molinolo A., Perou C.M., Lanari C. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. *Breast Cancer Res Treat*. 2010 [Epub ahead of print].
278. Hou X., Kumar A., Lee C., Wang B., Arjunan P., Dong L., Maminishkis A., Tang Z., Li Y., Zhang F., Zhang S.-Z, Wardega P., Chakrabarty S., Liu B., Wu Z., Colosi P., Fariss R.N., Lennartsson J., Nussenblatt R., Gutkind J.S., Cao Y., and Li X. PDGF-CC blockade inhibits pathological angiogenesis by acting on multiple cellular and molecular targets. *Proc. Natl. Acad. Sci. U.S.A.*, **107**:12216-12221, 2010.
279. Facchinetti M.M., Gandini N.A., Fermento M.E., Sterin-Speziale N.B., Ji Y., Patel V., Gutkind J.S., Rivadulla M.G., Curino A.C. The expression of sphingosine kinase-1 in head and neck carcinoma. *Cells Tissues Organs*, **192**:314-324, 2010.
280. Dwyer J., Le Guelte A., Sumbal M., Carlotti A., Douguet L., Gutkind J.S., Grange P.A., Dupin N., and Gavard J. The human herpes virus 8 G-protein coupled receptor signaling pathway is linked to the loss of vascular integrity in human Kaposi Sarcoma. *Oncogene*, 2010 [Epub ahead of print].
281. Knox S.M., Lombaert M. A., Reed X., Vitale-Cross L., Gutkind J.S. and Hoffman M.P. Parasympathetic innervation maintains epithelial progenitor cells during salivary organogenesis. *Science*, **329**:1645-1647, 2010.
282. Bhirde A.A., Patel S., Sousa A.A., Patel V., Molinolo A.A., Ji Y., Leapman R.D., Gutkind J.S., and Rusling J.F. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. *Nanomedicine* **5**:1535-1546, 2010.
283. Sosa M.S., Lopez-Haber C., Yang C., Wang H., Lemmon M.A., Busillo J.M., Luo J., Benovic J.L., Klein-Szanto A., Yagi H., Gutkind J.S., Parsons R.E., and Kazanietz M.G. Identification of the Rac-GEF P-REX1 as an essential mediator of ErbB signaling in breast cancer. *Mol. Cell*, **40**:877-892, 2010.

284. Suyarnsestakorn C., Thanasupawat T., Leelahavanichkul K., Gutkind J.S., and Mutirangura A. ATM nuclear localization in head and neck cancer cells is PPP2R2B-dependent. *Asian Biomedicine*, **4**: 3, 2010.
285. Cervenka I., Wolf J., Masek J., Krejci P., Wilcox W.R., Kozubík A., Schulte G., Gutkind* J.S., and Bryja* V. Mitogen-activated protein kinases promote WNT/{beta}-catenin signaling via phosphorylation of LRP6. *Mol. Cell. Biol*. **31:** 179-189, 2011.
286. Bottino M.C., Cerliani J.P., Rojas P., Giulianelli S., Soldati R., Mondillo C., Gorostiaga M.A., Pignataro O.P., Calvo J.C., Gutkind J.S., Amornphimoltham P., Molinolo A.A., Lüthy I.A., and Lanari C. Classical membrane progesterone receptors in murine mammary carcinomas: agonistic effects of progestins and RU-486 mediating rapid non-genomic effects. *Breast Cancer Res Treat*., **126**:621-636, 2011.
287. Munge B.S., Coffey A.L., Doucette J.M., Somba B.K., Malhotra R., Patel V., Gutkind J.S., and Rusling J.F. Nanostructured Immunosensor for Attomolar Detection of Cancer Biomarker Interleukin-8 Using Massively Labeled Superparamagnetic Particles. *Angew Chem Int Ed Engl*. [Epub ahead of print], 2011,
288. Chikkaveeraiah B.V., Mani V., Patel V., Gutkind J.S., and Rusling J.F. Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum. *Biosens. Bioelectron*., **26**:4477-4483, 2011.
289. Maruyama T., Li J., Vaque J.P., Konkel J., Wang W., Zhang B., Zhang P., Zamarron B., Wu Y., Zhuang Y., Gutkind J.S., and Chen WJ. Control of the differentiation of regulatory T cells and T(H)17 cells by the DNA-binding inhibitor Id3. *Nature Immunol*., **12:** 86-95, 2011.
290. Szabo R., Rasmussen A.L., Moyer A.B., Kosa P., Schafer J.M., Molinolo A.A., Gutkind J.S., and Bugge T.H. c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase. *Oncogene*, **30:** 2003-2016, 2011.
291. Sansing H.A., Sarkeshik A., Yates J.R., Patel V., Gutkind J.S., Yamada K.M., and Berrier A.L. Integrin αβ1, α(v)β, α(6)β effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance. *Biochem. Biophys. Res. Commun*., **406:** 171-176, 2011.
292. Cerliani J.P., Guillardoy T., Giulianelli S., Vaque J.P., Gutkind J.S., Vanzulli S.I., Martins R., Zeitlin E., Lamb C.A., and Lanari C. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. *Cancer Res*. **71**:3720-3731, 2011.
293. Fujita M., Cha Y.R., Pham V.N., Sakurai A., Roman B.L., Gutkind J.S., Weinstein B.M. Assembly and patterning of the vascular network of the vertebrate hindbrain. *Development*, **138**:1705-1715, 2011.
294. Giulianelli S., Herschkowitz J.I., Patel V., Lamb C.A., Gutkind J.S., Molinolo A., Perou C.M., Lanari C. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. *Breast Cancer Res Treat*., **129**:49-67, 2011.
295. Bhirde AA, Liu G, Jin A, Iglesias-Bartolome R, Sousa AA, Leapman RD, Gutkind JS, Lee S, Chen X. Combining portable Raman probes with nanotubes for theranostic applications. *Theranostics*, **1**:310-321. 2011.
296. Sakurai A., Jian X., Lee C.J., Manavski Y., Chavakis E., Donaldson J., Randazzo P.A., and Gutkind J.S. PIP5 kinase and GEP100/Brag2 mediate anti-angiogenic signaling by Semaphorin 3E-Plexin-D1 through Arf6. *J. Biol. Chem*., **286**:34335-343345, 2011.

297. Martin D., Galisteo R., Molinolo A.A., Wetzker R., Hirsch E., and Gutkind J.S. PI3Kγ mediates Kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. *Cancer Cell*, **19:** 805-813, 2011.
298. Yagi H., Tan W., Dillenburg-Pilla P., Armando S., Amornphimoltham P., Simaan M., Weigert R., Molinolo A.A., Bouvier M., and Gutkind J.S. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. *Science Signaling*, **4**:ra60, 2011.
299. Patel V., Marsh C.A., Dorsam R.T., Masedunskas A., Amornphimoltham P., Nathan C.O., Singh B., Weigert R., Molinolo A.A., and Gutkind J.S. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. *Cancer Research*, **71**:7103-7112, 2011.
300. Dutzan N., Vernal R., Vaque J.P., García-Sesnich J., Hernandez M., Abusleme L., Dezerega A., Gutkind J.S., and Gamonal J. Interleukin-21 Expression and its Association with Pro-Inflammatory Cytokines in Untreated Chronic Periodontitis Patients. *J Periodontol*. [Epub ahead of print], 2011.
301. Leopoldino A.M., Squarize C.H., Garcia C.B., Almeida L.O., Pestana C.R., Polizello A.C., Uyemura S.A., Tajara E.H., Gutkind J.S., and Curti C. Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling. *Mol Cell Biochem*. [Epub ahead of print], 2011.
302. Bian Y., Hall B., Sun Z.J., Molinolo A., Chen W., Gutkind J.S., Waes C.V., and Kulkarni A.B. Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. *Oncogene*, [Epub ahead of print], 2011.
303. Berendsen A.D., Fisher L.W., Kilts T., Owens R.T., Robey P.G., Gutkind J.S., and Young M.F. Modulation of Canonical Wnt Signaling by the ECM Component, Biglycan. *Proc. Natl. Acad. Sci., USA*, **108**:17022-17027, 2011.

Peer Reviewed Review Articles

304. Gutkind J.S. The pathway linking G protein-coupled receptors to divergent MAP kinase cascades. *J. Biol. Chem.*, Minireview **273:**1839-42, 1998.
305. Gutkind J.S. Cell growth control by G protein-coupled receptors: From signal transduction to signal integration. *Oncogene*, **17:**1331-1342, 1998.
306. Winn D.M, Sandberg A.N., Horowitz A.M., Diehl S.R, Gutkind J.S., and Kleinman D.V. Reducing the burden of oral and pharyngeal cancers. *J. Calif. Dental Assoc.*, **26:**445-54, 1998.
307. Gutkind J.S. Regulation of Mitogen-Activated Protein Kinase signaling networks by G protein-coupled receptors. *Science* STKE series, Science's STKE -- Gutkind 2000 (40): 1re, 2000.
308. Marinissen M.J., and Gutkind J.S.: G Protein-coupled receptors and signaling networks: emerging paradigms. *Trends Pharmacol. Sci*., **22**:368-76, 2001.
309. Pece S., and Gutkind J.S. E-cadherin and Hakai: signalling, remodeling or destruction? *Nature Cell Biol.*, **4**:E72-4, 2002.
310. Sodhi A., Montaner S., and Gutkind J.S. Viral hijacking of G-protein-coupled-receptor signalling networks. *Nature Rev. Mol. Cell. Biol.*, **12**:998-1012, 2004.

311. Vázquez-Prado J., Basile J., and Gutkind J.S. Modular Architecture and Novel Protein-Protein Interactions Regulating RGS-Containing RhoGEFs. *Methods in Enzymology*, **390**:259-285, 2004
312. Dennis P.A., Van Waes C., Gutkind J.S., Kellar K.J, Vinson C., Mukhin A.G., Spitz M.R., Bailey-Wilson J.E., Yeh G.C., Anderson L.M., and Wiest J.S. The Biology of Tobacco and Nicotine: Bench to Bedside. *Cancer Epidemiol. Biomarkers Prev.*, **14**:764-767, 2005.
313. Marinissen M.J. and Gutkind J.S. Scaffold proteins dictate Rho GTPase-signaling specificity. *Trends Biochem. Sci.*, **30**:423-426, 2005.
314. Castellone M.D., Teramoto H., and Gutkind J.S. COX-2 and colorectal cancer: The β-catenin connection. *Cancer Research*, **66**:11085-11088, 2006.
315. Gavard J. and Gutkind J.S. VE-cadherin takes a walk on the wild side. *Med Sci* (Paris), **23**:119-121, 2007.
316. Turjanski A.G., Vaqué J.P., and Gutkind J.S. MAP Kinases and the Control of Nuclear Events. *Oncogene*, **26**:3240-3253, 2007.
317. Dorsam R. and Gutkind J.S. G protein-coupled receptors and cancer. *Nature Reviews Cancer*, **7**:79-94, 2007.
318. Gavard J. and Gutkind J.S. VE-Cadherin and Claudin-5: It takes two to tango. *Nature Cell Biology*, **10**:883-885, 2008.
319. Molinolo A.A., Amornphimoltham P., Squarize C.H., Castilho R.M., Patel V., and Gutkind J.S. Dysregulated molecular networks in head and neck carcinogenesis. *Oral Oncology*, **45**:324-334, 2009.
320. Gutkind J.S. and Offermanns S. A new G_q-initiated MAPK signaling pathway in the heart. *Dev. Cell*, **16**:163-164, 2009.
321. Vitale-Cross L., Czerninski R., Amornphimoltham P., Patel V., Molinolo A.A., and Gutkind J.S Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer. *Cancer Prevention Research*, **2**:419-422, 2009.
322. Martin D. and Gutkind J.S. Kaposi's sarcoma virally encoded, G-protein-coupled receptor: a paradigm for paracrine transformation. *Methods in Enzymology* **460**:125-150, 2009.
323. El-Naggar A.K., Kaye F.J., Shirazi Y., Gutkind J.S., Forastiere A.A.Meeting report--the NIDCR 2(nd) Salivary Gland Tumor Meeting. *Head Neck* 31:1542-1543, 2009.
324. Martin D. and Gutkind J.S. Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. *Oncogene* **27**, Suppl 2:S31-S42, 2009.
325. Rusling J.F., Kumar C.V., Gutkind J.S., and Patel V. Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. *Analyst*. [Epub ahead of print] 2010
326. Iglesias-Bartolome R. and Gutkind J.S. Keeping the epidermal stem cell niche in shape. *Cell Stem Cell*, **7**:143-145, 2010.
327. Iglesias-Bartolome R. and Gutkind J.S. Signaling circuitries and stem cell fate: To be or not to be. *Current Opinion in Cell Biology*, **23**:716-723, 2011.
328. Sakurai A., Doci C., and Gutkind J.S. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer. *Cell Research*, [Epub ahead of print], 2011.
329. Patel V., Iglesias-Bartolome R., Siegele B., Marsh C.A., Leelahavanichkul K., Molinolo A.A., and Gutkind J.S. Cellular systems for studying human oral squamous cell carcinomas. *Adv Exp Med Biol.* **720**:27-38, 2011.

Book Chapters and Proceedings

330. Castren E., Kurihara M., Gutkind J.S., and Saavedra J.M. Atrial natriuretic peptide receptors in thymus and spleen of young spontaneously hypertensive rats. In "Advances in Atrial Peptide Research". *ASH Symposium Series* volume II, 243-247, 1988.
331. Gutkind J.S., Kurihara M., Castren E., and Saavedra J.M. Atrial natriuretic peptide receptors in rat sympathetic ganglia: alterations in genetically hypertensive rats. In "Advances in Atrial Peptide Research", ASH Symposium Series volume II, 261-265, 1988.
332. Saavedra J.M., Castren E., Gutkind J.S., Kurihara M., and Nazarali A.J. Atrial natriuretic peptide and the autonomous nervous system. In "Atrial Natriuretic Peptides". Edited by R. Quirion and W.K. Samson. Boca Raton, Florida: CRC press, Inc., 209-220, 1989.
333. Saavedra J.M., Castren E., Gutkind J.S., and Nazarali A.J. Regulation of brain atrial natriuretic peptide and angiotensin receptors: Quantitative autoradiographic studies. *Internatl. Rev. of Neurobiol.*, **31:**257-296, 1989.
334. Gutkind J.S., Lacal P.M., Benhamou M., Siraganian R.P., and Robbins K.C. Evidence for protein-tyrosine kinase involvement in non-proliferative signal transduction. *Proc. II Internatl. Symp. on Oncogenes*, Spain, 101-132, 1991.
335. Siraganian R.P., Benhamou M., Stephan V., Gutkind J.S., and Robbins K.C. Tyrosine phosphorylation coupled to IgE receptor-mediated signal transduction and histamine release. Proc. XIV Internatl. Cong. Allergeology and Clinical Immunology. In "Progress in Allergy and Clinical Immunology". *Vol. 2.* Edited by T. Miyamoto and M. Okuda. Toronto: Hogrefe and Huber, 354-359, 1992.
336. Gutkind J.S., Crespo P., Coso O., Kalinec G., and Xu N. Proliferative signaling through muscarinic acetylcholine receptors: a model for receptors coupled to heterotrimeric G Proteins. *In "Molecular Mechanisms of Muscarinic Acetylcholine Receptor Function"*. Edited by Jurgen Wess. R.G Landes, Publisher,103-141, 1995.
337. Gutkind J.S., Crespo P., Coso O., and Xu N. Signaling from heterotrimeric G proteins to MAP kinase involves βγ subunits acting on a *ras*-dependent pathway. In "The Molecular Basis of Cancer and Their Clinical Applications", Spanish Association for Cancer Research. Edited by J. C. Lacal, E. B. Olaetxea and R. Perona, pp. 137-146, 1996.
338. Gutkind J.S. and Vitale-Cross L. The pathway linking small GTP-binding proteins of the Rho Family to cytoskeletal components and novel signaling kinase cascades. *Seminars Cell. Dev. Biol.*, **7:**683-690, 1996.
339. Gutkind J.S., Vitale-Cross L., Crespo P., Xu N., Teramoto H., and Coso O.A. The pathway connecting G protein-coupled receptors to the nucleus involves small GTP-binding proteins acting on divergent MAP kinase cascades. In "Studies in Stomatology and Craniofacial Biology". Edited by M.M. Cohen, Jr., and B. Baum, IOS Press, pp. 39-57, 1997.

340. Gutkind J.S., Coso O.A., Xu N. G_{12} and G_{13} α subunits of heterotrimeric G proteins: A novel family of oncogenes. In "G Proteins, Receptors, and Disease". Edited by A.M. Spiegel. Humana Press, pp. 101-117, 1998.
341. Teramoto H. and Gutkind J.S. The pathway connecting muscarinic acetylcholine receptors to the nucleus involves small GTP-binding proteins. *Tanpakushitsu Kakusan Koso*, **43:**35-41 1998.
342. Gutkind J.S. Signaling from the Membrane to the Nucleus through Divergent MAP Kinase Cascades. In *Cell Signal Transduction, Implications for Drug Discovery.* IBC Library Series. Edited by Minden S.A. and Guttry P., pp. 39-60, 1998.
343. Chiariello M. and Gutkind J.S. Regulation of MAP Kinases by G Protein-Coupled Receptors. *Methods in Enzymology*, **345**:437-47, 2002.
344. Gutkind J.S. Editor, *Book on Signaling Networks and Cell Cycle Control.* Humana Press, 2000.
345. Fukuhara S., Marinissen M.J, Chiariello M., and Gutkind J.S. The pathway linking G protein-coupled receptors to the nucleus. In *"Signaling Networks and Cell Cycle Control", Humana Press*, Totowa, NJ, JS Gutkind Ed., 83-98, 2000.
346. Todd R., Gutkind J.S., Shillitoe E.J., and Wong D.T. Solid Tumors: Microarray analysis of oral cancers. In *"Microarrays and Cancer Research", Biotechniques Press*, Westborough, MA, J.A. Warrington, R. Todd, and D. Wong, Eds., 139-153, 2002.
347. Sodhi A., Montaner S., and Gutkind J.S. Molecular mechanisms of cancer. In "Signal Transduction and Human Disease". Edited by T. Finkel and J.S. Gutkind. Hoboken, NJ: John Wiley & Sons, pp 71-142, 2003.
348. Patel V., Leethanakul C., Amornphimoltham P., and Gutkind J.S. Squamous carcinomas of the head and neck: Novel genomic approaches. In "Head and Neck Cancer Emerging Perspectives". Edited by J.F. Ensley, J.S. Gutkind, J.R. Jacobs, and S.M. Lippman. Academic Press, San Diego, CA. pp. 509-522, 2003.
349. Rosenfeldt H., Marinissen M.J., and Gutkind J.S. G-protein-coupled receptors, cell transformation, and signal fidelity. In "Handbook of Cell Signaling", Edited by R.A. Bradshaw and E. A. Dennis. Elsevier Publishing Co., pp 589-599, 2003.
350. Crespo P. and Gutkind J.S. Activation of MAPKs by G Protein-Coupled Receptors. *Methods Mol. Biol*., **250**:203-210, 2004.
351. Teramoto H. and Gutkind J.S. The Mitogen-Activated Protein Kinase family. In "Encyclopedia of Biological Chemistry". Edited by W.J. Lennarz and M.D. Lane Elsevier, Oxford, **2:**737-742, 2005.
352. Sodhi A. and Gutkind J.S. Endothelial cell transformation by the Kaposi's Sarcoma Herpesvirus. In "Encyclopedia of the Microvasculature", Edited by D. Shapro and J.A. Madri. Elsevier Science U.S.A., **147**:993-998, 2006.
353. Montaner S. and Gutkind J.S. The vascular endothelium as a target for hemorrhagic fever viruses. In "Encyclopedia of the Microvasculature", Edited by D. Shapro and J.A. Madri. Elsevier Science U.S.A., **102**:689, 694, 2006.
354. Marinissen M.J. and Gutkind J.S. Regulation of JNK by small GTPases. In "The JNK Signaling Pathway". Edited by A. Lin. Landes Bioscience, Georgetown, TX, **2**:13-28, 2006.
355. Gavard J. and Gutkind J.S. A Molecular Crosstalk between E-cadherin and EGFR Signaling Networks. In "Signaling Network in Cancer Therapy". Edited by J.D. Haley and W.J. Gullick. Humana Press Inc, 20:139-154, 2008.

356. Palmby T.R., Rosenfeldt H., and Gutkind J.S. G Protein-coupled receptors, signal fidelity and cell transformation. In “The Handbook of Cell Signaling Second Edition”, Edited by R. Bradshaw and E. Dennis. Elsevier Science U.S.A., **201**:1635-1648, 2009.
357. Amornphimoltham P., Patel V., Molinolo A., and Gutkind J.S. Head and Neck Cancer and the PI3K/Akt/mTOR signaling network: Novel Molecular Targeted Therapies. In “Signaling Pathways in Squamous Cancer." Edited by C. VanWaes and A. Glick. Springer Science & Business Media U.S.A., in press.
358. Chiariello M., Vaque J.P., and Gutkind J.S. Activation of MAPKs by G Protein-Coupled Receptors. “MAPK Protocol Book.” Edited by R. Seger. Humana Press Inc., in press.
359. Vázquez-Prado J. and Gutkind J.S. RGS-RhoGEFs and other RGS multidomain proteins as Effector Molecules in GPCR-Dependent and GPCR-independent Cell Signaling. In “G Protein Coupled Receptors.” Edited by S. Siehler and G. Milligan. Cambridge University Press, U.K., in press.
360. Leelahavanichkul K, Gutkind JS. Oral and Pharyngeal Epithelial Cell Culture. In “Methods in Molecular Biology”, Second Edition, Edited by SH Randell, Humana Press, in press.